NOR-SOLIDARITY First Interim Report

Inge Christoffer Olsen, PhD

04 January, 2021

Table of Contents

[2 Introduction 3](#_Toc60611032)

[3 Inclusion status 4](#_Toc60611033)

[3.1 Inclusion rate 4](#_Toc60611034)

[3.2 Inclusion by hospital 5](#_Toc60611035)

[3.3 By treatment 6](#_Toc60611036)

[4 Patient flow 10](#_Toc60611037)

[5 Demographics 11](#_Toc60611038)

[6 Exposure 25](#_Toc60611039)

[7 Efficacy 25](#_Toc60611040)

[7.1 Mortality 25](#_Toc60611041)

[7.1.1 Descriptives 25](#_Toc60611042)

[7.1.2 Plots 27](#_Toc60611043)

[7.1.3 Efficacy estimates 36](#_Toc60611044)

[7.2 Viral load 38](#_Toc60611045)

[7.2.1 Plots 38](#_Toc60611046)

[7.2.2 Marginal probability estimates by treatment group and difference 42](#_Toc60611047)

[7.3 Viral load subgroup analyses 44](#_Toc60611048)

[7.3.1 Plots, Hydroxychloroquine 44](#_Toc60611049)

[7.3.2 Marginal probability estimates by treatment group and difference Hydroxychloroquine 56](#_Toc60611050)

[7.3.3 Plots Remdesivir 61](#_Toc60611051)

[7.3.4 Marginal probability estimates by treatment group and difference Remdesivir 73](#_Toc60611052)

[7.4 Respiratory failure by pO2/FiO2-ratio 78](#_Toc60611053)

[7.4.1 Plots 78](#_Toc60611054)

[7.4.2 Marginal probability estimates by treatment group and difference 82](#_Toc60611055)

[7.5 Dichotomous endpoints 83](#_Toc60611056)

[7.5.1 Descriptives 83](#_Toc60611057)

[7.5.2 Marginal probability estimates by treatment group and difference 85](#_Toc60611058)

[7.6 Inflammatory laboratory parameters 86](#_Toc60611059)

[7.6.1 Descriptives 86](#_Toc60611060)

[7.6.2 Plots 110](#_Toc60611061)

[7.6.3 Efficacy estimates 122](#_Toc60611062)

[7.7 SARS-CoV2 antibodies at day 90 127](#_Toc60611063)

[7.7.1 Descriptives 127](#_Toc60611064)

[7.7.2 Marginal probability estimates by treatment group and difference 128](#_Toc60611065)

[7.8 Time to last discharge 129](#_Toc60611066)

[7.8.1 HCQ 129](#_Toc60611067)

[7.8.2 Remdesivir 132](#_Toc60611068)

[8 Adverse Events 135](#_Toc60611069)

[8.1 AE Summary 135](#_Toc60611070)

[8.2 By System Organ Class and Preferred Term 135](#_Toc60611071)

[8.3 Serious Adverse Events 140](#_Toc60611072)


[8.4 Suspected Unexpected Serious Adverse Reaction 142](#_Toc60611073)

# Introduction


This is the report for the first interim analysis of the NOR-SOLIDARITY trial. The data are based on an export from the Viedoc electronic data capture at “2020-10-16 08:41:09” system time stamped “ous\_20201016\_084109”. While the results are based on real data, the treatment allocation has been drawn randomly for this report. Thus, this is a mock-up report intended to show how the final report will look like, without showing the actual results of the trial and the treatment differences. There were 181 included patients.

# Inclusion status




## Inclusion rate



## Inclusion by hospital



## By treatment



# Patient flow

## Note: Using an external vector in selections is ambiguous.  
## ℹ Use `all\_of(group)` instead of `group` to silence this message.  
## ℹ See <https://tidyselect.r-lib.org/reference/faq-external-vector.html>.  
## This message is displayed once per session.

Patient flow total

|  |  |
| --- | --- |
| Parameter | Total |
| Enrolled | 186 (100%) |
| Randomised | 185 (99.5%) |
| Included in FAS | 181 (97.3%) |
| Excluded from FAS, No post-randomisation information | 4 (2.2%) |
| Excluded from FAS, incorrect inclusion | 1 (0.5%) |

Patient flow by arm

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC | SOC + HCQ | SOC + Remdesivir |
| Randomised | 88 (100%) | 54 (100%) | 43 (100%) |
| Included in FAS | 87 (98.9%) | 52 (96.3%) | 42 (97.7%) |
| Excluded from FAS, No post-randomisation information | 1 (1.1%) | 1 (1.9%) | 1 (2.3%) |
| Excluded from FAS, incorrect inclusion | 0 (0%) | 1 (1.9%) | 0 (0%) |

Patient flow during study (FAS)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Reason | Standard of care (SOC) | Remdesivir + SOC | Hydroxychloroquine + SOC | Total |
| Voluntary discontinuation by the patient | 3 | 4 | 0 | 7 |
| Patient lost to follow-up | 2 | 2 | 2 | 6 |
| Death | 2 | 5 | 5 | 12 |
| Other | 4 | 2 | 0 | 6 |
| Completed | 76 | 29 | 45 | 150 |

# Demographics

Demographics, all patients (FAS)

|  |  |
| --- | --- |
| Parameter | All patients (N=181) |
| **Demographics** |  |
| Age (years) | 59.8 (15.3) |
| Female, n (%) | 62 (34.3%) |
| Body Mass Index (kg/m2) | 28 (5) |
| Body Mass Index (kg/m2) | 27 (25 - 31) |
| Symptoms prior to admission (days) | 8 (4.9) |
| P/F-ratio at admittance (kPa) | 41 (13) |
| P/F-ratio < 40kPa, n (%) | 77 (43%) |
| Temperature (°C) | 37.4 (0.9) |
| Admitted to ward, n(%) | 171 (94.5%) |
| Admitted to ICU, n(%) | 10 (5.5%) |
| WHO Moderate disease state (4-5), n(%) | 171 (94.5%) |
| WHO Severe disease state (6-9), n(%) | 10 (5.5%) |
| WHO Severe disease state (6), n(%) | 5 (2.8%) |
| WHO Severe disease state (5), n(%) | 90 (49.7%) |
| **Comorbidities** |  |
| Chronic cardiac disease, including congenital heart disease | 28 (15.6%) |
| Chronic pulmonary disease, n(%) | 10 (5.6%) |
| Ever smoking, n(%) | 71 (39.4%) |
| Hypertension, n(%) | 55 (30.6%) |
| Diabetes, n(%) | 31 (17.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 44 (26.8%) |
| **Co-medications** |  |
| Steroids | 8 (4.5%) |
| Other immunomodulatory drugs | 8 (4.5%) |
| ACE inhibitor | 12 (6.7%) |
| AT-II blockers | 30 (16.8%) |
| **Hematology** |  |
| Hemoglobin (g/dL) | 13.2 (12.3 - 14.1) |
| WBC (x109/L) | 6.2 (4.7 - 8.7) |
| Neutrophils (x109/L) | 4.3 (3 - 6.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.4) |
| Platelet counts (x10^9/L) | 202.5 (158.5 - 270.5) |
| **Inflammatory markers** |  |
| CRP (mg/L) | 70 (36.5 - 137.5) |
| Procalcitonin (µg/L) | 0.12 (0.1 - 0.21) |
| Ferritin (µg/L) | 613 (319 - 1173) |
| **Other** |  |
| LDH (U/L) | 277 (214 - 360) |
| D-dimer (mg/L FEU) | 0.68 (0.45 - 1.12) |
| AST | 39 (27.2 - 59) |
| ALT | 33 (20 - 58) |
| eGFR (mL/min/1.73 m2) | 89.7 (74.2 - 105.5) |
| **Viral count** |  |
| Viral count (log10 counts/1000 cells) | 2 (1.6) |
| **Anti-SARS-CoV-2 Antibodies** |  |
| **Supplementary baseline information** |  |
| Systolic Blood Pressure (mmHg) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 74 (11) |
| Mean Arterial Blood Pressure (mmHg) | 91 (12) |
| SOFA score | 1.6 (1.6) |
| Chronic kidney disease, n(%) | 11 (6.1%) |
| Autoimmune disease, n(%) | 8 (4.4%) |
| Cognitive impairment/dementia, n(%) | 4 (2.2%) |
| Neurological disorder, n(%) | 7 (3.9%) |
| Cancer, n(%) | 13 (7.2%) |
| Cirrhosis, n(%) | 0 (0%) |
| Asthma, n(%) | 22 (12.2%) |
| HIV, n(%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |

Demographics, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 58.2 (14.6) | 59.1 (16.7) | 63.8 (14.7) |
| Female, n (%) | 29 (33.3%) | 15 (28.8%) | 18 (42.9%) |
| Body Mass Index (kg/m2) | 29 (5) | 27 (4) | 27 (5) |
| Body Mass Index (kg/m2) | 28 (25 - 33) | 27 (24 - 29) | 27 (25 - 29) |
| Symptoms prior to admission (days) | 8 (4.9) | 7.3 (4.7) | 9 (5.2) |
| P/F-ratio at admittance (kPa) | 42 (12) | 43 (13) | 38 (15) |
| P/F-ratio < 40kPa, n (%) | 37 (43%) | 20 (39.2%) | 20 (47.6%) |
| Temperature (°C) | 37.3 (1) | 37.5 (0.9) | 37.5 (0.9) |
| Admitted to ward, n(%) | 84 (96.6%) | 49 (94.2%) | 38 (90.5%) |
| Admitted to ICU, n(%) | 3 (3.4%) | 3 (5.8%) | 4 (9.5%) |
| WHO Moderate disease state (4-5), n(%) | 83 (95.4%) | 49 (94.2%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 4 (4.6%) | 3 (5.8%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | 2 (2.3%) | 2 (3.8%) | 1 (2.4%) |
| WHO Severe disease state (5), n(%) | 41 (47.1%) | 24 (46.2%) | 25 (59.5%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 13 (15.1%) | 9 (17.3%) | 6 (14.3%) |
| Chronic pulmonary disease, n(%) | 3 (3.5%) | 4 (7.7%) | 3 (7.1%) |
| Ever smoking, n(%) | 34 (39.5%) | 22 (42.3%) | 15 (35.7%) |
| Hypertension, n(%) | 24 (27.9%) | 18 (34.6%) | 13 (31%) |
| Diabetes, n(%) | 13 (15.1%) | 7 (13.5%) | 11 (26.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 26 (32.5%) | 10 (22.7%) | 8 (20%) |
| **Co-medications** |  |  |  |
| Steroids | 3 (3.5%) | 3 (5.9%) | 2 (4.8%) |
| Other immunomodulatory drugs | 3 (3.5%) | 3 (5.9%) | 2 (4.8%) |
| ACE inhibitor | 6 (7%) | 3 (5.9%) | 3 (7.1%) |
| AT-II blockers | 13 (15.1%) | 7 (13.7%) | 10 (23.8%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 13.1 (12.1 - 14.1) | 13.6 (13 - 14.4) | 12.9 (11.6 - 14) |
| WBC (x109/L) | 6.3 (4.5 - 9) | 6.2 (4.8 - 8.1) | 6 (4.8 - 7.9) |
| Neutrophils (x109/L) | 4.5 (2.8 - 7) | 4.6 (3 - 6.4) | 3.9 (3.2 - 5.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.3) | 1.1 (0.8 - 1.4) | 1.1 (0.7 - 1.5) |
| Platelet counts (x10^9/L) | 204 (151.2 - 268.2) | 197 (163 - 268.8) | 208.5 (170.2 - 271.2) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 70.5 (40.8 - 138.8) | 75 (43 - 137.8) | 61 (27 - 127) |
| Procalcitonin (µg/L) | 0.12 (0.1 - 0.2) | 0.12 (0.1 - 0.2) | 0.15 (0.1 - 0.39) |
| Ferritin (µg/L) | 626 (321.5 - 1116) | 578 (315.2 - 1209.5) | 573 (316 - 1194) |
| **Other** |  |  |  |
| LDH (U/L) | 279 (216 - 368) | 290 (216 - 353.5) | 274 (209 - 325) |
| D-dimer (mg/L FEU) | 0.6 (0.41 - 1.18) | 0.64 (0.5 - 1.02) | 0.9 (0.51 - 1.12) |
| AST | 41 (29 - 57) | 43 (27 - 65) | 32.5 (24 - 61.2) |
| ALT | 39 (22 - 61) | 30 (22.5 - 58.5) | 23.5 (18.2 - 49) |
| eGFR (mL/min/1.73 m2) | 91.6 (79.8 - 106) | 88.8 (76.1 - 104.6) | 83.3 (67.8 - 97.3) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 1.9 (1.6) | 2.1 (1.7) | 2.2 (1.5) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 125 (18) | 125 (17) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 73 (11) | 74 (12) | 73 (12) |
| Mean Arterial Blood Pressure (mmHg) | 91 (12) | 91 (12) | 91 (12) |
| SOFA score | 1.8 (1.8) | 1.3 (1.4) | 1.5 (1.5) |
| Chronic kidney disease, n(%) | 5 (5.8%) | 2 (3.8%) | 4 (9.5%) |
| Autoimmune disease, n(%) | 3 (3.5%) | 3 (5.8%) | 2 (4.8%) |
| Cognitive impairment/dementia, n(%) | 2 (2.3%) | 1 (1.9%) | 1 (2.4%) |
| Neurological disorder, n(%) | 3 (3.5%) | 3 (5.8%) | 1 (2.4%) |
| Cancer, n(%) | 6 (7%) | 6 (11.5%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 6 (7%) | 11 (21.2%) | 5 (11.9%) |
| HIV, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

Demographics, HCQ (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=54) | SOC + HCQ (N=52) |
| **Demographics** |  |  |
| Age (years) | 57.4 (16.4) | 59.1 (16.7) |
| Female, n (%) | 17 (31.5%) | 15 (28.8%) |
| Body Mass Index (kg/m2) | 28 (5) | 27 (4) |
| Body Mass Index (kg/m2) | 28 (25 - 31) | 27 (24 - 29) |
| Symptoms prior to admission (days) | 8.1 (5.5) | 7.3 (4.7) |
| P/F-ratio at admittance (kPa) | 40 (11) | 43 (13) |
| P/F-ratio < 40kPa, n (%) | 25 (46.3%) | 20 (39.2%) |
| Temperature (°C) | 37.2 (1) | 37.5 (0.9) |
| Admitted to ward, n(%) | 52 (96.3%) | 49 (94.2%) |
| Admitted to ICU, n(%) | 2 (3.7%) | 3 (5.8%) |
| WHO Moderate disease state (4-5), n(%) | 52 (96.3%) | 49 (94.2%) |
| WHO Severe disease state (6-9), n(%) | 2 (3.7%) | 3 (5.8%) |
| WHO Severe disease state (6), n(%) | 1 (1.9%) | 2 (3.8%) |
| WHO Severe disease state (5), n(%) | 30 (55.6%) | 24 (46.2%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 8 (15.1%) | 9 (17.3%) |
| Chronic pulmonary disease, n(%) | 1 (1.9%) | 4 (7.7%) |
| Ever smoking, n(%) | 22 (41.5%) | 22 (42.3%) |
| Hypertension, n(%) | 14 (26.4%) | 18 (34.6%) |
| Diabetes, n(%) | 9 (17%) | 7 (13.5%) |
| Obese (BMI > 30 kg/m2), n(%) | 14 (29.2%) | 10 (22.7%) |
| **Co-medications** |  |  |
| Steroids | 2 (3.8%) | 3 (5.9%) |
| Other immunomodulatory drugs | 2 (3.8%) | 3 (5.9%) |
| ACE inhibitor | 2 (3.8%) | 3 (5.9%) |
| AT-II blockers | 9 (17%) | 7 (13.7%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13 (12.1 - 14.1) | 13.6 (13 - 14.4) |
| WBC (x109/L) | 6.6 (4.9 - 9.2) | 6.2 (4.8 - 8.1) |
| Neutrophils (x109/L) | 4.8 (3 - 7.4) | 4.6 (3 - 6.4) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.5) | 1.1 (0.8 - 1.4) |
| Platelet counts (x10^9/L) | 217 (160 - 288.8) | 197 (163 - 268.8) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 70.5 (40.8 - 137) | 75 (43 - 137.8) |
| Procalcitonin (µg/L) | 0.15 (0.1 - 0.25) | 0.12 (0.1 - 0.2) |
| Ferritin (µg/L) | 677 (312.2 - 1049.5) | 578 (315.2 - 1209.5) |
| **Other** |  |  |
| LDH (U/L) | 280 (220.8 - 358.8) | 290 (216 - 353.5) |
| D-dimer (mg/L FEU) | 0.6 (0.43 - 1.15) | 0.64 (0.5 - 1.02) |
| AST | 39.5 (28.8 - 58.2) | 43 (27 - 65) |
| ALT | 40.5 (22.2 - 63.8) | 30 (22.5 - 58.5) |
| eGFR (mL/min/1.73 m2) | 95.7 (83.2 - 106.1) | 88.8 (76.1 - 104.6) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 1.8 (1.6) | 2.1 (1.7) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 128 (19) | 125 (17) |
| Diastolic Blood Pressure (mmHg) | 75 (10) | 74 (12) |
| Mean Arterial Blood Pressure (mmHg) | 93 (11) | 91 (12) |
| SOFA score | 1.7 (1.8) | 1.3 (1.4) |
| Chronic kidney disease, n(%) | 2 (3.8%) | 2 (3.8%) |
| Autoimmune disease, n(%) | 2 (3.8%) | 3 (5.8%) |
| Cognitive impairment/dementia, n(%) | 1 (1.9%) | 1 (1.9%) |
| Neurological disorder, n(%) | 0 (0%) | 3 (5.8%) |
| Cancer, n(%) | 3 (5.7%) | 6 (11.5%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 5 (9.4%) | 11 (21.2%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Demographics, Remdesivir (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=57) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |
| Age (years) | 56.9 (12.1) | 63.8 (14.7) |
| Female, n (%) | 19 (33.3%) | 18 (42.9%) |
| Body Mass Index (kg/m2) | 29 (5) | 27 (5) |
| Body Mass Index (kg/m2) | 29 (26 - 33) | 27 (25 - 29) |
| Symptoms prior to admission (days) | 8.4 (5.8) | 9 (5.2) |
| P/F-ratio at admittance (kPa) | 43 (12) | 38 (15) |
| P/F-ratio < 40kPa, n (%) | 20 (35.7%) | 20 (47.6%) |
| Temperature (°C) | 37.4 (1) | 37.5 (0.9) |
| Admitted to ward, n(%) | 55 (96.5%) | 38 (90.5%) |
| Admitted to ICU, n(%) | 2 (3.5%) | 4 (9.5%) |
| WHO Moderate disease state (4-5), n(%) | 54 (94.7%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 3 (5.3%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | 2 (3.5%) | 1 (2.4%) |
| WHO Severe disease state (5), n(%) | 23 (40.4%) | 25 (59.5%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 8 (14.3%) | 6 (14.3%) |
| Chronic pulmonary disease, n(%) | 3 (5.4%) | 3 (7.1%) |
| Ever smoking, n(%) | 18 (32.1%) | 15 (35.7%) |
| Hypertension, n(%) | 17 (30.4%) | 13 (31%) |
| Diabetes, n(%) | 7 (12.5%) | 11 (26.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 19 (35.8%) | 8 (20%) |
| **Co-medications** |  |  |
| Steroids | 2 (3.6%) | 2 (4.8%) |
| Other immunomodulatory drugs | 2 (3.6%) | 2 (4.8%) |
| ACE inhibitor | 5 (8.9%) | 3 (7.1%) |
| AT-II blockers | 9 (16.1%) | 10 (23.8%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13.3 (12.1 - 14.1) | 12.9 (11.6 - 14) |
| WBC (x109/L) | 6.6 (4.3 - 8.7) | 6 (4.8 - 7.9) |
| Neutrophils (x109/L) | 3.8 (2.5 - 6.7) | 3.9 (3.2 - 5.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.3) | 1.1 (0.7 - 1.5) |
| Platelet counts (x10^9/L) | 202 (144 - 263.2) | 208.5 (170.2 - 271.2) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 67 (37.5 - 139.2) | 61 (27 - 127) |
| Procalcitonin (µg/L) | 0.1 (0.1 - 0.19) | 0.15 (0.1 - 0.39) |
| Ferritin (µg/L) | 622 (372.8 - 1153) | 573 (316 - 1194) |
| **Other** |  |  |
| LDH (U/L) | 279 (209 - 369) | 274 (209 - 325) |
| D-dimer (mg/L FEU) | 0.6 (0.41 - 1.2) | 0.9 (0.51 - 1.12) |
| AST | 45 (29 - 57.2) | 32.5 (24 - 61.2) |
| ALT | 41 (25.5 - 70) | 23.5 (18.2 - 49) |
| eGFR (mL/min/1.73 m2) | 91.8 (83.1 - 106.6) | 83.3 (67.8 - 97.3) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 2 (1.7) | 2.2 (1.5) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 124 (18) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 73 (11) | 73 (12) |
| Mean Arterial Blood Pressure (mmHg) | 90 (12) | 91 (12) |
| SOFA score | 1.7 (1.5) | 1.5 (1.5) |
| Chronic kidney disease, n(%) | 3 (5.4%) | 4 (9.5%) |
| Autoimmune disease, n(%) | 2 (3.6%) | 2 (4.8%) |
| Cognitive impairment/dementia, n(%) | 1 (1.8%) | 1 (2.4%) |
| Neurological disorder, n(%) | 3 (5.4%) | 1 (2.4%) |
| Cancer, n(%) | 3 (5.4%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 4 (7.1%) | 5 (11.9%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Missing values, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 0 (0%) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 7 (8%), 7 (8%) | 8 (15.4%), 8 (15.4%) | 2 (4.8%), 2 (4.8%) |
| Symptoms prior to admission (days) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| P/F-ratio at admittance (kPa) | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| P/F-ratio < 40kPa, n (%) | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Temperature (°C) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Chronic pulmonary disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Ever smoking, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Hypertension, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Diabetes, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Obese (BMI > 30 kg/m2), n(%) | 7 (8%) | 8 (15.4%) | 2 (4.8%) |
| **Co-medications** |  |  |  |
| Steroids | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Other immunomodulatory drugs | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| ACE inhibitor | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| AT-II blockers | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 1 (1.1%) | 2 (3.8%) | 0 (0%) |
| WBC (x109/L) | 0 (0%) | 1 (1.9%) | 0 (0%) |
| Neutrophils (x109/L) | 3 (3.4%) | 6 (11.5%) | 1 (2.4%) |
| Lymphocytes (x109/L) | 2 (2.3%) | 6 (11.5%) | 1 (2.4%) |
| Platelet counts (x10^9/L) | 1 (1.1%) | 2 (3.8%) | 0 (0%) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| Procalcitonin (µg/L) | 32 (36.8%) | 14 (26.9%) | 12 (28.6%) |
| Ferritin (µg/L) | 4 (4.6%) | 2 (3.8%) | 3 (7.1%) |
| **Other** |  |  |  |
| LDH (U/L) | 2 (2.3%) | 5 (9.6%) | 1 (2.4%) |
| D-dimer (mg/L FEU) | 8 (9.2%) | 8 (15.4%) | 3 (7.1%) |
| AST | 6 (6.9%) | 3 (5.8%) | 2 (4.8%) |
| ALT | 2 (2.3%) | 2 (3.8%) | 4 (9.5%) |
| eGFR (mL/min/1.73 m2) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 28 (32.2%) | 11 (21.2%) | 9 (21.4%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| Sero converted (RBD ≤ 5) | 26 (29.9%) | 15 (28.8%) | 13 (31%) |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| SOFA score | 7 (8%) | 3 (5.8%) | 1 (2.4%) |
| Chronic kidney disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Autoimmune disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cognitive impairment/dementia, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Neurological disorder, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cancer, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cirrhosis, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| HIV, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

# Exposure

Exposure to study treatment

|  |  |  |
| --- | --- | --- |
| Parameter | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Total dose (mg), median (IQR) | 1100 (850 - 3300) | 1100 (500 - 6400) |
| Treatment duration, median (IQR) | 6 (4 - 9) | 6 (3 - 9) |
| Number of doses given, median (IQR) | 7 (4 - 10) | 6 (4 - 10) |
| Patients with any treatment discrepencies, n (%) | 8 (33.3%) | 7 (29.2%) |

# Efficacy

## Mortality

### Descriptives

All arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 2 | 87 | 2.3 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |
| Remdesivir + SOC | 5 | 42 | 11.9 |










HCQ (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 1 | 54 | 1.9 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |

Remdesivir (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 1 | 57 | 1.8 |
| Remdesivir + SOC | 5 | 42 | 11.9 |

### Plots







### Efficacy estimates

Relative risk estimates and p-values

|  |  |  |
| --- | --- | --- |
| Timeframe, Population | Relative risk | P-value |
| Full timeframe, All | Not applicable | 0.082 |
| Full timeframe, Hydroxychloroquine only | 4 (95% CI 0.81 to 19.82) | 0.090 |
| Full timeframe, Remdesivir only | 5.53 (95% CI 1.09 to 28.11) | 0.039 |
| Censored at 60 days, All | Not applicable | 0.100 |
| Censored at 60 days, Hydroxychloroquine only | 3.46 (95% CI 0.6 to 19.99) | 0.165 |
| Censored at 60 days, Remdesivir only | 5.53 (95% CI 1.09 to 28.11) | 0.039 |
| Censored at 28 days, All | Not applicable | 0.306 |
| Censored at 28 days, Hydroxychloroquine only | 3.46 (95% CI 0.6 to 19.99) | 0.165 |
| Censored at 28 days, Remdesivir only | 3.73 (95% CI 0.51 to 27.14) | 0.194 |

## Viral load

### Plots



### Marginal probability estimates by treatment group and difference

Estimated treatment effect, Hydroxychloroquine













|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | -0.212 | -0.287 | -0.138 | 0.000 |
| Hydroxychloroquine + SOC | Slope 1st week | -0.135 | -0.212 | -0.059 | 0.001 |
| Hydroxychloroquine + SOC | Difference in slope | 0.077 | -0.030 | 0.184 | 0.159 |
| Standard of care (SOC) | Level at day 10 | 0.280 | -0.143 | 0.703 | 0.195 |
| Hydroxychloroquine + SOC | Level at day 10 | 0.507 | 0.120 | 0.894 | 0.010 |
| Hydroxychloroquine + SOC | Difference at day 10 | 0.227 | -0.347 | 0.800 | 0.438 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | -0.214 | -0.300 | -0.128 | 0.000 |
| Remdesivir + SOC | Slope 1st week | -0.291 | -0.388 | -0.194 | 0.000 |
| Remdesivir + SOC | Difference in slope | -0.077 | -0.206 | 0.053 | 0.244 |
| Standard of care (SOC) | Level at day 10 | 0.774 | 0.349 | 1.198 | 0.000 |
| Remdesivir + SOC | Level at day 10 | 0.227 | -0.180 | 0.635 | 0.274 |
| Remdesivir + SOC | Difference at day 10 | -0.546 | -1.134 | 0.042 | 0.069 |

## Viral load subgroup analyses

### Plots, Hydroxychloroquine



### Marginal probability estimates by treatment group and difference Hydroxychloroquine

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | RBD < 5 | Slope 1st week by treatment and subgroup | -0.285 | -0.423 | -0.146 | 0.000 |
| Standard of care (SOC) | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.139 | -0.246 | -0.032 | 0.011 |
| Hydroxychloroquine + SOC | RBD < 5 | Slope 1st week by treatment and subgroup | -0.293 | -0.406 | -0.179 | 0.000 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.161 | -0.306 | -0.017 | 0.029 |
| Hydroxychloroquine + SOC | RBD < 5 | Treatment effect (Difference in slope) | -0.008 | -0.187 | 0.171 | 0.931 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Treatment effect (Difference in slope) | -0.022 | -0.202 | 0.158 | 0.809 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Treatment/Subgroup interaction | -0.014 | -0.268 | 0.239 | 0.912 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | age < 60 years | Slope 1st week by treatment and subgroup | -0.253 | -0.374 | -0.132 | 0.000 |
| Standard of care (SOC) | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.149 | -0.255 | -0.043 | 0.006 |
| Hydroxychloroquine + SOC | age < 60 years | Slope 1st week by treatment and subgroup | -0.167 | -0.279 | -0.055 | 0.003 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.295 | -0.411 | -0.179 | 0.000 |
| Hydroxychloroquine + SOC | age < 60 years | Treatment effect (Difference in slope) | 0.086 | -0.079 | 0.251 | 0.308 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Treatment effect (Difference in slope) | -0.146 | -0.303 | 0.011 | 0.068 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Treatment/Subgroup interaction | -0.232 | -0.459 | -0.004 | 0.046 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High CRP | Slope 1st week by treatment and subgroup | -0.190 | -0.292 | -0.088 | 0.000 |
| Standard of care (SOC) | Low CRP | Slope 1st week by treatment and subgroup | -0.217 | -0.348 | -0.085 | 0.001 |
| Hydroxychloroquine + SOC | High CRP | Slope 1st week by treatment and subgroup | -0.232 | -0.340 | -0.123 | 0.000 |
| Hydroxychloroquine + SOC | Low CRP | Slope 1st week by treatment and subgroup | -0.237 | -0.359 | -0.115 | 0.000 |
| Hydroxychloroquine + SOC | High CRP | Treatment effect (Difference in slope) | -0.042 | -0.190 | 0.107 | 0.584 |
| Hydroxychloroquine + SOC | Low CRP | Treatment effect (Difference in slope) | -0.020 | -0.200 | 0.159 | 0.823 |
| Hydroxychloroquine + SOC | Low CRP | Treatment/Subgroup interaction | 0.021 | -0.212 | 0.254 | 0.859 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High Ferritin | Slope 1st week by treatment and subgroup | -0.179 | -0.281 | -0.077 | 0.001 |
| Standard of care (SOC) | Low Ferritin | Slope 1st week by treatment and subgroup | -0.235 | -0.370 | -0.101 | 0.001 |
| Hydroxychloroquine + SOC | High Ferritin | Slope 1st week by treatment and subgroup | -0.188 | -0.293 | -0.083 | 0.000 |
| Hydroxychloroquine + SOC | Low Ferritin | Slope 1st week by treatment and subgroup | -0.279 | -0.417 | -0.141 | 0.000 |
| Hydroxychloroquine + SOC | High Ferritin | Treatment effect (Difference in slope) | -0.009 | -0.155 | 0.138 | 0.909 |
| Hydroxychloroquine + SOC | Low Ferritin | Treatment effect (Difference in slope) | -0.044 | -0.237 | 0.149 | 0.658 |
| Hydroxychloroquine + SOC | Low Ferritin | Treatment/Subgroup interaction | -0.035 | -0.277 | 0.207 | 0.777 |













Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.263 | -0.392 | -0.135 | 0.000 |
| Standard of care (SOC) | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.164 | -0.269 | -0.059 | 0.002 |
| Hydroxychloroquine + SOC | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.283 | -0.403 | -0.162 | 0.000 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.202 | -0.312 | -0.092 | 0.000 |
| Hydroxychloroquine + SOC | Symptom duration < 7 days | Treatment effect (Difference in slope) | -0.019 | -0.195 | 0.157 | 0.830 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Treatment effect (Difference in slope) | -0.038 | -0.190 | 0.115 | 0.628 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Treatment/Subgroup interaction | -0.018 | -0.251 | 0.214 | 0.877 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High viral load | Slope 1st week by treatment and subgroup | -0.370 | -0.474 | -0.266 | 0.000 |
| Standard of care (SOC) | Low viral load | Slope 1st week by treatment and subgroup | -0.030 | -0.135 | 0.075 | 0.575 |
| Hydroxychloroquine + SOC | High viral load | Slope 1st week by treatment and subgroup | -0.384 | -0.483 | -0.286 | 0.000 |
| Hydroxychloroquine + SOC | Low viral load | Slope 1st week by treatment and subgroup | -0.063 | -0.171 | 0.044 | 0.248 |
| Hydroxychloroquine + SOC | High viral load | Treatment effect (Difference in slope) | -0.014 | -0.157 | 0.129 | 0.848 |
| Hydroxychloroquine + SOC | Low viral load | Treatment effect (Difference in slope) | -0.033 | -0.183 | 0.117 | 0.664 |
| Hydroxychloroquine + SOC | Low viral load | Treatment/Subgroup interaction | -0.019 | -0.227 | 0.188 | 0.855 |

### Plots Remdesivir



### Marginal probability estimates by treatment group and difference Remdesivir

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | RBD < 5 | Slope 1st week by treatment and subgroup | -0.338 | -0.490 | -0.185 | 0.000 |
| Standard of care (SOC) | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.105 | -0.237 | 0.028 | 0.123 |
| Remdesivir + SOC | RBD < 5 | Slope 1st week by treatment and subgroup | -0.225 | -0.353 | -0.096 | 0.001 |
| Remdesivir + SOC | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.047 | -0.200 | 0.105 | 0.543 |
| Remdesivir + SOC | RBD < 5 | Treatment effect (Difference in slope) | 0.113 | -0.087 | 0.313 | 0.267 |
| Remdesivir + SOC | RBD ≥ 5 | Treatment effect (Difference in slope) | 0.057 | -0.145 | 0.259 | 0.579 |
| Remdesivir + SOC | RBD ≥ 5 | Treatment/Subgroup interaction | -0.056 | -0.340 | 0.228 | 0.700 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | age < 60 years | Slope 1st week by treatment and subgroup | -0.216 | -0.316 | -0.116 | 0.000 |
| Standard of care (SOC) | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.258 | -0.401 | -0.115 | 0.000 |
| Remdesivir + SOC | age < 60 years | Slope 1st week by treatment and subgroup | -0.253 | -0.373 | -0.132 | 0.000 |
| Remdesivir + SOC | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.108 | -0.223 | 0.007 | 0.066 |
| Remdesivir + SOC | age < 60 years | Treatment effect (Difference in slope) | -0.037 | -0.194 | 0.120 | 0.645 |
| Remdesivir + SOC | age ≥ 60 years | Treatment effect (Difference in slope) | 0.150 | -0.033 | 0.334 | 0.108 |
| Remdesivir + SOC | age ≥ 60 years | Treatment/Subgroup interaction | 0.187 | -0.054 | 0.429 | 0.128 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High CRP | Slope 1st week by treatment and subgroup | -0.234 | -0.347 | -0.122 | 0.000 |
| Standard of care (SOC) | Low CRP | Slope 1st week by treatment and subgroup | -0.227 | -0.351 | -0.104 | 0.000 |
| Remdesivir + SOC | High CRP | Slope 1st week by treatment and subgroup | -0.149 | -0.256 | -0.042 | 0.007 |
| Remdesivir + SOC | Low CRP | Slope 1st week by treatment and subgroup | -0.172 | -0.310 | -0.034 | 0.015 |
| Remdesivir + SOC | High CRP | Treatment effect (Difference in slope) | 0.085 | -0.070 | 0.241 | 0.283 |
| Remdesivir + SOC | Low CRP | Treatment effect (Difference in slope) | 0.056 | -0.130 | 0.241 | 0.557 |
| Remdesivir + SOC | Low CRP | Treatment/Subgroup interaction | -0.030 | -0.272 | 0.212 | 0.811 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High Ferritin | Slope 1st week by treatment and subgroup | -0.193 | -0.306 | -0.080 | 0.001 |
| Standard of care (SOC) | Low Ferritin | Slope 1st week by treatment and subgroup | -0.257 | -0.379 | -0.135 | 0.000 |
| Remdesivir + SOC | High Ferritin | Slope 1st week by treatment and subgroup | -0.147 | -0.266 | -0.027 | 0.017 |
| Remdesivir + SOC | Low Ferritin | Slope 1st week by treatment and subgroup | -0.188 | -0.319 | -0.056 | 0.005 |
| Remdesivir + SOC | High Ferritin | Treatment effect (Difference in slope) | 0.047 | -0.118 | 0.211 | 0.580 |
| Remdesivir + SOC | Low Ferritin | Treatment effect (Difference in slope) | 0.069 | -0.110 | 0.248 | 0.448 |
| Remdesivir + SOC | Low Ferritin | Treatment/Subgroup interaction | 0.023 | -0.221 | 0.266 | 0.854 |

Estimated treatment effect, Remdesivir





|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.286 | -0.396 | -0.175 | 0.000 |
| Standard of care (SOC) | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.169 | -0.294 | -0.044 | 0.008 |
| Remdesivir + SOC | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.202 | -0.324 | -0.081 | 0.001 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.154 | -0.268 | -0.040 | 0.008 |
| Remdesivir + SOC | Symptom duration < 7 days | Treatment effect (Difference in slope) | 0.083 | -0.081 | 0.247 | 0.322 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Treatment effect (Difference in slope) | 0.015 | -0.154 | 0.184 | 0.861 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Treatment/Subgroup interaction | -0.068 | -0.304 | 0.168 | 0.572 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High viral load | Slope 1st week by treatment and subgroup | -0.386 | -0.490 | -0.282 | 0.000 |
| Standard of care (SOC) | Low viral load | Slope 1st week by treatment and subgroup | -0.043 | -0.159 | 0.073 | 0.467 |
| Remdesivir + SOC | High viral load | Slope 1st week by treatment and subgroup | -0.280 | -0.376 | -0.185 | 0.000 |
| Remdesivir + SOC | Low viral load | Slope 1st week by treatment and subgroup | 0.035 | -0.095 | 0.166 | 0.593 |
| Remdesivir + SOC | High viral load | Treatment effect (Difference in slope) | 0.106 | -0.035 | 0.247 | 0.142 |
| Remdesivir + SOC | Low viral load | Treatment effect (Difference in slope) | 0.079 | -0.096 | 0.253 | 0.377 |
| Remdesivir + SOC | Low viral load | Treatment/Subgroup interaction | -0.027 | -0.252 | 0.197 | 0.812 |

## Respiratory failure by pO2/FiO2-ratio

### Plots



### Marginal probability estimates by treatment group and difference

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | 1.174 | 0.488 | 1.860 | 0.001 |
| Hydroxychloroquine + SOC | Slope 1st week | 0.356 | -0.291 | 1.004 | 0.281 |
| Hydroxychloroquine + SOC | Difference in slope | -0.818 | -1.762 | 0.126 | 0.089 |
| Standard of care (SOC) | Level at day 10 | 56.915 | 49.883 | 63.948 | 0.000 |
| Hydroxychloroquine + SOC | Level at day 10 | 53.614 | 46.819 | 60.410 | 0.000 |
| Hydroxychloroquine + SOC | Difference at day 10 | -3.301 | -13.080 | 6.478 | 0.508 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | 0.471 | -0.023 | 0.964 | 0.062 |
| Remdesivir + SOC | Slope 1st week | 0.549 | -0.033 | 1.131 | 0.065 |
| Remdesivir + SOC | Difference in slope | 0.078 | -0.685 | 0.841 | 0.841 |
| Standard of care (SOC) | Level at day 10 | 49.779 | 44.693 | 54.865 | 0.000 |
| Remdesivir + SOC | Level at day 10 | 48.355 | 42.338 | 54.372 | 0.000 |
| Remdesivir + SOC | Difference at day 10 | -1.424 | -9.302 | 6.455 | 0.723 |

## Dichotomous endpoints

### Descriptives

Hydroxycholoquine

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Mortality during hospitalisation | 1 (1.9%) | 5 (9.6%) |
| Mortality (censored at day 28) | 1 (1.9%) | 5 (9.6%) |
| Mortality (censored at day 60) | 1 (1.9%) | 5 (9.6%) |
| WHO disease state progression | 4 (7.4%) | 13 (25%) |
| WHO disease state progression (censoreda at day 28) | 4 (7.4%) | 13 (25%) |
| WHO disease state progression (censoreda at day 60) | 4 (7.4%) | 13 (25%) |
| Mechanical ventilation during hospitalisation | 2 (3.7%) | 6 (11.5%) |
| Mechanical ventilation (censored at day 28) | 2 (3.7%) | 6 (11.5%) |
| Mechanical ventilation (censored at day 60) | 2 (3.7%) | 6 (11.5%) |
| Admission to ICU during hospitalisation | 6 (11.1%) | 13 (25%) |
| Admission to ICU (censored at day 28) | 6 (11.1%) | 13 (25%) |
| Admission to ICU (censored at day 60) | 6 (11.1%) | 13 (25%) |

Figures are number of patients with the outcome and percent (%)

Remdesivir

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC |
| Mortality during hospitalisation | 3 (5.3%) | 3 (7.1%) |
| Mortality (censored at day 28) | 2 (3.5%) | 1 (2.4%) |
| Mortality (censored at day 60) | 3 (5.3%) | 2 (4.8%) |
| WHO disease state progression | 8 (14%) | 7 (16.7%) |
| WHO disease state progression (censoreda at day 28) | 8 (14%) | 7 (16.7%) |
| WHO disease state progression (censoreda at day 60) | 8 (14%) | 7 (16.7%) |
| Mechanical ventilation during hospitalisation | 5 (8.8%) | 8 (19%) |
| Mechanical ventilation (censored at day 28) | 5 (8.8%) | 8 (19%) |
| Mechanical ventilation (censored at day 60) | 5 (8.8%) | 8 (19%) |
| Admission to ICU during hospitalisation | 9 (15.8%) | 10 (23.8%) |
| Admission to ICU (censored at day 28) | 9 (15.8%) | 10 (23.8%) |
| Admission to ICU (censored at day 60) | 9 (15.8%) | 10 (23.8%) |

Figures are number of patients with the outcome and percent (%)

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 1.9% (-1.7 to 5.4) | 9.6% (1.6 to 17.6) | 7.8% (-1 to 16.5) |
| Mortality (censored at day 28) | 1.9% (-1.7 to 5.4) | 9.6% (1.6 to 17.6) | 7.8% (-1 to 16.5) |
| Mortality (censored at day 60) | 1.9% (-1.7 to 5.4) | 9.6% (1.6 to 17.6) | 7.8% (-1 to 16.5) |
| WHO disease state progression | 7.4% (0.4 to 14.4) | 25% (13.2 to 36.8) | 17.6% (3.9 to 31.3) |
| WHO disease state progression (censoreda at day 28) | 7.4% (0.4 to 14.4) | 25% (13.2 to 36.8) | 17.6% (3.9 to 31.3) |
| WHO disease state progression (censoreda at day 60) | 7.4% (0.4 to 14.4) | 25% (13.2 to 36.8) | 17.6% (3.9 to 31.3) |
| Mechanical ventilation during hospitalisation | 3.7% (-1.3 to 8.7) | 11.5% (2.9 to 20.2) | 7.8% (-2.2 to 17.9) |
| Mechanical ventilation (censored at day 28) | 3.7% (-1.3 to 8.7) | 11.5% (2.9 to 20.2) | 7.8% (-2.2 to 17.9) |
| Mechanical ventilation (censored at day 60) | 3.7% (-1.3 to 8.7) | 11.5% (2.9 to 20.2) | 7.8% (-2.2 to 17.9) |
| Admission to ICU during hospitalisation | 11.1% (2.7 to 19.5) | 25% (13.2 to 36.8) | 13.9% (-0.6 to 28.3) |
| Admission to ICU (censored at day 28) | 11.1% (2.7 to 19.5) | 25% (13.2 to 36.8) | 13.9% (-0.6 to 28.3) |
| Admission to ICU (censored at day 60) | 11.1% (2.7 to 19.5) | 25% (13.2 to 36.8) | 13.9% (-0.6 to 28.3) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 5.3% (-0.5 to 11.1) | 7.1% (-0.6 to 14.9) | 1.9% (-7.8 to 11.6) |
| Mortality (censored at day 28) | 3.5% (-1.3 to 8.3) | 2.4% (-2.2 to 7) | -1.1% (-7.8 to 5.5) |
| Mortality (censored at day 60) | 5.3% (-0.5 to 11.1) | 4.8% (-1.7 to 11.2) | -0.5% (-9.2 to 8.2) |
| WHO disease state progression | 14% (5 to 23.1) | 16.7% (5.4 to 27.9) | 2.6% (-11.8 to 17.1) |
| WHO disease state progression (censoreda at day 28) | 14% (5 to 23.1) | 16.7% (5.4 to 27.9) | 2.6% (-11.8 to 17.1) |
| WHO disease state progression (censoreda at day 60) | 14% (5 to 23.1) | 16.7% (5.4 to 27.9) | 2.6% (-11.8 to 17.1) |
| Mechanical ventilation during hospitalisation | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Mechanical ventilation (censored at day 28) | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Mechanical ventilation (censored at day 60) | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Admission to ICU during hospitalisation | 15.8% (6.3 to 25.3) | 23.8% (10.9 to 36.7) | 8% (-8 to 24) |
| Admission to ICU (censored at day 28) | 15.8% (6.3 to 25.3) | 23.8% (10.9 to 36.7) | 8% (-8 to 24) |
| Admission to ICU (censored at day 60) | 15.8% (6.3 to 25.3) | 23.8% (10.9 to 36.7) | 8% (-8 to 24) |

## Inflammatory laboratory parameters

### Descriptives

CRP (mg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 81.74 (66.4) | 94.6 (71.76) |
| 0 days | Median [IQR] | 60.5 [38.5 - 108] | 73 [33 - 151.25] |
| 0 days | Missing / Non-Missing | 0 / 54 | 0 / 52 |
| 1 days | Mean (SD) | 93.69 (78.3) | 86.41 (67.44) |
| 1 days | Median [IQR] | 66 [47 - 107] | 69.5 [40.25 - 129] |
| 1 days | Missing / Non-Missing | 10 / 43 | 8 / 44 |
| 2 days | Mean (SD) | 94.15 (76.35) | 81.28 (77.07) |
| 2 days | Median [IQR] | 73 [42.75 - 120.25] | 67 [28 - 113] |
| 2 days | Missing / Non-Missing | 10 / 40 | 4 / 49 |
| 3 days | Mean (SD) | 90.28 (73.25) | 78.52 (76.43) |
| 3 days | Median [IQR] | 70 [36.75 - 121.75] | 61 [20.75 - 104.5] |
| 3 days | Missing / Non-Missing | 10 / 34 | 5 / 42 |
| 4 days | Mean (SD) | 103.22 (91.19) | 78.38 (72.07) |
| 4 days | Median [IQR] | 77 [41 - 122] | 70 [20.5 - 97] |
| 4 days | Missing / Non-Missing | 5 / 29 | 6 / 35 |
| 5 days | Mean (SD) | 92.19 (90.71) | 74.43 (60.02) |
| 5 days | Median [IQR] | 57.5 [34.75 - 92.75] | 67 [22 - 98] |
| 5 days | Missing / Non-Missing | 2 / 28 | 3 / 33 |
| 6 days | Mean (SD) | 81.48 (81.6) | 72.89 (72.12) |
| 6 days | Median [IQR] | 49 [37.75 - 95.5] | 43 [19.75 - 105.5] |
| 6 days | Missing / Non-Missing | 3 / 24 | 4 / 26 |
| 7 days | Mean (SD) | 68.53 (67.53) | 89.53 (88.02) |
| 7 days | Median [IQR] | 37 [22 - 107.25] | 55 [15.25 - 143.75] |
| 7 days | Missing / Non-Missing | 4 / 18 | 3 / 24 |
| 8 days | Mean (SD) | 51.87 (50.19) | 103.4 (106.9) |
| 8 days | Median [IQR] | 37 [15 - 78] | 66.5 [19.25 - 170.75] |
| 8 days | Missing / Non-Missing | 2 / 18 | 6 / 18 |
| 9 days | Mean (SD) | 48.78 (44.86) | 82.47 (97.76) |
| 9 days | Median [IQR] | 30 [12 - 84] | 36 [10.5 - 136.5] |
| 9 days | Missing / Non-Missing | 3 / 17 | 0 / 19 |
| 10 days | Mean (SD) | 34.43 (42.73) | 87.04 (101.14) |
| 10 days | Median [IQR] | 19 [7.03 - 31.5] | 44 [15 - 143] |
| 10 days | Missing / Non-Missing | 3 / 14 | 0 / 13 |
| 11 days | Mean (SD) | 42.67 (38.9) | 99.6 (135.55) |
| 11 days | Median [IQR] | 41 [11 - 52] | 51 [9.5 - 119] |
| 11 days | Missing / Non-Missing | 4 / 9 | 1 / 11 |
| 12 days | Mean (SD) | 87 (64.32) | 133.4 (209.25) |
| 12 days | Median [IQR] | 88 [49.5 - 106.25] | 44 [11 - 110] |
| 12 days | Missing / Non-Missing | 3 / 6 | 2 / 9 |
| 13 days | Mean (SD) | 114.4 (82.61) | 86.12 (119.82) |
| 13 days | Median [IQR] | 115 [46 - 144] | 35 [7 - 106] |
| 13 days | Missing / Non-Missing | 3 / 5 | 2 / 9 |
| 14 days | Mean (SD) | 64.53 (85.71) | 39.58 (52.11) |
| 14 days | Median [IQR] | 33 [22.03 - 75.5] | 20 [4.6 - 50] |
| 14 days | Missing / Non-Missing | 0 / 4 | 0 / 9 |

CRP (mg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 89.45 (67.05) | 99.73 (65.7) |
| 0 days | Median [IQR] | 79 [45 - 116] | 84 [45.25 - 160.25] |
| 0 days | Missing / Non-Missing | 0 / 57 | 2 / 40 |
| 1 days | Mean (SD) | 95.04 (70.1) | 108.25 (74.49) |
| 1 days | Median [IQR] | 84 [41.25 - 124] | 99 [59.75 - 153.5] |
| 1 days | Missing / Non-Missing | 11 / 46 | 6 / 36 |
| 2 days | Mean (SD) | 96.94 (64.29) | 87.53 (81.93) |
| 2 days | Median [IQR] | 92 [46.5 - 130.5] | 57.5 [29.75 - 109.5] |
| 2 days | Missing / Non-Missing | 6 / 47 | 3 / 38 |
| 3 days | Mean (SD) | 97.54 (59.65) | 85 (78.64) |
| 3 days | Median [IQR] | 85 [52 - 128.5] | 54.5 [25 - 133.5] |
| 3 days | Missing / Non-Missing | 9 / 39 | 4 / 32 |
| 4 days | Mean (SD) | 108.38 (86.75) | 80.6 (82.79) |
| 4 days | Median [IQR] | 99 [39.5 - 136] | 47 [20.25 - 108.25] |
| 4 days | Missing / Non-Missing | 5 / 35 | 5 / 28 |
| 5 days | Mean (SD) | 108.7 (96.47) | 73.31 (72.62) |
| 5 days | Median [IQR] | 90 [33.5 - 151] | 48 [17 - 112.75] |
| 5 days | Missing / Non-Missing | 8 / 30 | 7 / 22 |
| 6 days | Mean (SD) | 100.6 (91.07) | 68.23 (75.73) |
| 6 days | Median [IQR] | 73 [30.5 - 145] | 53 [9.23 - 69.5] |
| 6 days | Missing / Non-Missing | 6 / 31 | 4 / 22 |
| 7 days | Mean (SD) | 88.52 (76.26) | 71.62 (76.02) |
| 7 days | Median [IQR] | 67 [27.5 - 124.5] | 40.5 [11 - 131.25] |
| 7 days | Missing / Non-Missing | 4 / 26 | 0 / 22 |
| 8 days | Mean (SD) | 75.09 (69.79) | 89.2 (82.5) |
| 8 days | Median [IQR] | 43 [21 - 116.5] | 55 [28.5 - 140.5] |
| 8 days | Missing / Non-Missing | 0 / 27 | 2 / 15 |
| 9 days | Mean (SD) | 76.22 (74.03) | 78.91 (63) |
| 9 days | Median [IQR] | 40 [17.25 - 122.25] | 59 [29.5 - 110.5] |
| 9 days | Missing / Non-Missing | 4 / 20 | 4 / 11 |
| 10 days | Mean (SD) | 55.22 (63.13) | 58.83 (51.63) |
| 10 days | Median [IQR] | 26 [6.5 - 97.5] | 34 [17.5 - 99] |
| 10 days | Missing / Non-Missing | 6 / 14 | 2 / 12 |
| 11 days | Mean (SD) | 65.88 (43.57) | 70.27 (91.36) |
| 11 days | Median [IQR] | 55 [37 - 101] | 29 [13.5 - 90.5] |
| 11 days | Missing / Non-Missing | 4 / 13 | 3 / 11 |
| 12 days | Mean (SD) | 72.97 (59.47) | 55.07 (64.96) |
| 12 days | Median [IQR] | 72 [8 - 107] | 19 [12.25 - 90.75] |
| 12 days | Missing / Non-Missing | 3 / 13 | 3 / 10 |
| 13 days | Mean (SD) | 112.85 (87.65) | 62.2 (71.19) |
| 13 days | Median [IQR] | 99 [46 - 187] | 23 [14 - 92] |
| 13 days | Missing / Non-Missing | 2 / 13 | 2 / 9 |
| 14 days | Mean (SD) | 102.38 (105.72) | 54.83 (95.49) |
| 14 days | Median [IQR] | 35.5 [26.75 - 197.75] | 13.5 [7.85 - 43.75] |
| 14 days | Missing / Non-Missing | 2 / 8 | 0 / 8 |

Ferritin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 589.16 (535.63) | 1034.12 (805.55) |
| 0 days | Median [IQR] | 417.5 [245.75 - 794] | 965 [410.75 - 1236] |
| 0 days | Missing / Non-Missing | 4 / 50 | 0 / 52 |
| 1 days | Mean (SD) | 607.23 (358.39) | 1146.69 (856.92) |
| 1 days | Median [IQR] | 512 [345.5 - 982.5] | 1014 [528.5 - 1482] |
| 1 days | Missing / Non-Missing | 22 / 31 | 17 / 35 |
| 2 days | Mean (SD) | 715.86 (486.42) | 968.72 (770.49) |
| 2 days | Median [IQR] | 591.5 [291.75 - 1026] | 754.5 [487.75 - 1346] |
| 2 days | Missing / Non-Missing | 14 / 36 | 7 / 46 |
| 3 days | Mean (SD) | 849 (624.94) | 1266.92 (1007.05) |
| 3 days | Median [IQR] | 724 [335.5 - 1049.5] | 1071 [551.75 - 1701.25] |
| 3 days | Missing / Non-Missing | 13 / 31 | 11 / 36 |
| 4 days | Mean (SD) | 1263.33 (943.67) | 1321.28 (1482.37) |
| 4 days | Median [IQR] | 904.5 [633 - 1832.5] | 870 [466 - 1393] |
| 4 days | Missing / Non-Missing | 10 / 24 | 12 / 29 |
| 5 days | Mean (SD) | 1077.42 (780.56) | 1188.56 (1151.14) |
| 5 days | Median [IQR] | 819.5 [517.25 - 1732] | 872 [605 - 1158] |
| 5 days | Missing / Non-Missing | 6 / 24 | 11 / 25 |
| 6 days | Mean (SD) | 1005.1 (670.36) | 1269.61 (1285.12) |
| 6 days | Median [IQR] | 810 [470 - 1596] | 847 [464 - 1509.5] |
| 6 days | Missing / Non-Missing | 6 / 21 | 7 / 23 |
| 7 days | Mean (SD) | 1129.43 (757.63) | 1088.55 (735.31) |
| 7 days | Median [IQR] | 1044.5 [464.75 - 1670.25] | 857 [487.25 - 1521.25] |
| 7 days | Missing / Non-Missing | 8 / 14 | 5 / 22 |
| 8 days | Mean (SD) | 859.25 (722.24) | 1112.43 (656.31) |
| 8 days | Median [IQR] | 672.5 [414.75 - 1060.5] | 1032.5 [610.25 - 1497.25] |
| 8 days | Missing / Non-Missing | 4 / 16 | 10 / 14 |
| 9 days | Mean (SD) | 805.25 (646.14) | 973.13 (673.54) |
| 9 days | Median [IQR] | 576.5 [505.75 - 864.25] | 883.5 [397.75 - 1670.25] |
| 9 days | Missing / Non-Missing | 4 / 16 | 3 / 16 |
| 10 days | Mean (SD) | 748.73 (428.12) | 1429.45 (805.18) |
| 10 days | Median [IQR] | 728 [612 - 877.5] | 1301 [996 - 1925] |
| 10 days | Missing / Non-Missing | 6 / 11 | 4 / 9 |
| 11 days | Mean (SD) | 532.45 (211.27) | 1542 (1102.01) |
| 11 days | Median [IQR] | 564 [422 - 666] | 1178.5 [756.5 - 2708.75] |
| 11 days | Missing / Non-Missing | 4 / 9 | 4 / 8 |
| 12 days | Mean (SD) | 739.33 (423.02) | 1559 (1157.33) |
| 12 days | Median [IQR] | 665 [618 - 703] | 1127.5 [809.25 - 2327.75] |
| 12 days | Missing / Non-Missing | 3 / 6 | 5 / 6 |
| 13 days | Mean (SD) | 614.75 (272.49) | 1097.38 (950.91) |
| 13 days | Median [IQR] | 683.5 [536 - 762.25] | 941.5 [353.75 - 1528.75] |
| 13 days | Missing / Non-Missing | 4 / 4 | 3 / 8 |
| 14 days | Mean (SD) | 623 (15.56) | 859.88 (617.84) |
| 14 days | Median [IQR] | 623 [617.5 - 628.5] | 912 [346.25 - 1286.25] |
| 14 days | Missing / Non-Missing | 2 / 2 | 1 / 8 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 775.69 (578.52) | 1588.71 (3781.22) |
| 0 days | Median [IQR] | 581 [312.25 - 1210.5] | 650.5 [349.5 - 1233.75] |
| 0 days | Missing / Non-Missing | 3 / 54 | 4 / 38 |
| 1 days | Mean (SD) | 918.33 (582.36) | 1850.57 (3830.84) |
| 1 days | Median [IQR] | 767 [415 - 1226] | 768 [401 - 1554.5] |
| 1 days | Missing / Non-Missing | 24 / 33 | 19 / 23 |
| 2 days | Mean (SD) | 930.62 (625.27) | 1439.81 (2012.1) |
| 2 days | Median [IQR] | 930.5 [436.5 - 1258.25] | 994 [471.5 - 1443.75] |
| 2 days | Missing / Non-Missing | 11 / 42 | 9 / 32 |
| 3 days | Mean (SD) | 983.71 (568.54) | 1184.63 (1038.72) |
| 3 days | Median [IQR] | 905.5 [637 - 1222] | 930 [389 - 1678.5] |
| 3 days | Missing / Non-Missing | 14 / 34 | 12 / 24 |
| 4 days | Mean (SD) | 1072.2 (736.54) | 1609.28 (1055.03) |
| 4 days | Median [IQR] | 929 [567.25 - 1450] | 1506.5 [756.25 - 2438.75] |
| 4 days | Missing / Non-Missing | 10 / 30 | 15 / 18 |
| 5 days | Mean (SD) | 981.32 (587.48) | 1271.14 (842.99) |
| 5 days | Median [IQR] | 902 [618 - 1235] | 1242.5 [622.75 - 1506.75] |
| 5 days | Missing / Non-Missing | 13 / 25 | 15 / 14 |
| 6 days | Mean (SD) | 882.8 (454.6) | 1178.67 (858.86) |
| 6 days | Median [IQR] | 807 [545.5 - 1181.5] | 1004 [710.75 - 1240.5] |
| 6 days | Missing / Non-Missing | 7 / 30 | 8 / 18 |
| 7 days | Mean (SD) | 929.81 (486.93) | 1335.3 (1107.31) |
| 7 days | Median [IQR] | 815 [524 - 1275] | 1151.5 [757.5 - 1411.5] |
| 7 days | Missing / Non-Missing | 9 / 21 | 2 / 20 |
| 8 days | Mean (SD) | 722.09 (368.11) | 1470.11 (1473.63) |
| 8 days | Median [IQR] | 713 [508 - 911.5] | 796 [664 - 1702] |
| 8 days | Missing / Non-Missing | 4 / 23 | 8 / 9 |
| 9 days | Mean (SD) | 712.22 (445.17) | 907.13 (568.19) |
| 9 days | Median [IQR] | 576.5 [499.75 - 846] | 914.5 [608.25 - 1263] |
| 9 days | Missing / Non-Missing | 6 / 18 | 7 / 8 |
| 10 days | Mean (SD) | 624.08 (352.41) | 1044.5 (468.75) |
| 10 days | Median [IQR] | 613 [509 - 801] | 1045.5 [832.5 - 1415] |
| 10 days | Missing / Non-Missing | 7 / 13 | 6 / 8 |
| 11 days | Mean (SD) | 576.82 (358.13) | 754.67 (575.16) |
| 11 days | Median [IQR] | 564 [316.5 - 806] | 751 [291.5 - 1063.5] |
| 11 days | Missing / Non-Missing | 6 / 11 | 8 / 6 |
| 12 days | Mean (SD) | 681.77 (416.29) | 571.5 (315.14) |
| 12 days | Median [IQR] | 667 [603 - 839] | 591 [432 - 730.5] |
| 12 days | Missing / Non-Missing | 3 / 13 | 9 / 4 |
| 13 days | Mean (SD) | 834.18 (480.51) | 617.29 (302.46) |
| 13 days | Median [IQR] | 704 [593.5 - 863] | 598 [470 - 772.5] |
| 13 days | Missing / Non-Missing | 4 / 11 | 4 / 7 |
| 14 days | Mean (SD) | 713.43 (550.28) | 449.8 (230.68) |
| 14 days | Median [IQR] | 612 [490 - 693.5] | 396 [392 - 553] |
| 14 days | Missing / Non-Missing | 3 / 7 | 3 / 5 |

LDH (U/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 272.94 (113.82) | 317.49 (143.9) |
| 0 days | Median [IQR] | 245 [194 - 317.5] | 279 [223 - 377.5] |
| 0 days | Missing / Non-Missing | 3 / 51 | 1 / 51 |
| 1 days | Mean (SD) | 287.37 (116.27) | 332.73 (122.2) |
| 1 days | Median [IQR] | 274.5 [214.5 - 324.75] | 297 [257 - 378.25] |
| 1 days | Missing / Non-Missing | 23 / 30 | 26 / 26 |
| 2 days | Mean (SD) | 306.29 (136.31) | 306.74 (118.81) |
| 2 days | Median [IQR] | 283 [216 - 347.5] | 298.5 [226.75 - 354.75] |
| 2 days | Missing / Non-Missing | 19 / 31 | 15 / 38 |
| 3 days | Mean (SD) | 322.38 (165.32) | 350.53 (145.98) |
| 3 days | Median [IQR] | 287 [238 - 357] | 331.5 [230 - 434.75] |
| 3 days | Missing / Non-Missing | 15 / 29 | 15 / 32 |
| 4 days | Mean (SD) | 356.59 (126.63) | 335.52 (121.85) |
| 4 days | Median [IQR] | 312.5 [257.25 - 458.5] | 345 [227 - 398.5] |
| 4 days | Missing / Non-Missing | 12 / 22 | 18 / 23 |
| 5 days | Mean (SD) | 320.43 (118.91) | 355.05 (118.6) |
| 5 days | Median [IQR] | 294 [259 - 419] | 315 [290 - 460] |
| 5 days | Missing / Non-Missing | 9 / 21 | 15 / 21 |
| 6 days | Mean (SD) | 291.15 (111.53) | 312.59 (110.28) |
| 6 days | Median [IQR] | 281.5 [235.5 - 375] | 289 [220 - 379] |
| 6 days | Missing / Non-Missing | 7 / 20 | 13 / 17 |
| 7 days | Mean (SD) | 298.62 (90.19) | 292.14 (115.19) |
| 7 days | Median [IQR] | 260 [227 - 340] | 277 [239 - 345] |
| 7 days | Missing / Non-Missing | 9 / 13 | 6 / 21 |
| 8 days | Mean (SD) | 294.38 (109.13) | 340.23 (96.66) |
| 8 days | Median [IQR] | 264.5 [233 - 329.25] | 347 [256 - 393] |
| 8 days | Missing / Non-Missing | 4 / 16 | 11 / 13 |
| 9 days | Mean (SD) | 296.14 (136.79) | 321.14 (114.75) |
| 9 days | Median [IQR] | 282 [212 - 332] | 287.5 [238.75 - 402.75] |
| 9 days | Missing / Non-Missing | 6 / 14 | 5 / 14 |
| 10 days | Mean (SD) | 272.36 (122.93) | 335.75 (91.18) |
| 10 days | Median [IQR] | 227 [200.5 - 306.5] | 329.5 [274.75 - 382.25] |
| 10 days | Missing / Non-Missing | 6 / 11 | 5 / 8 |
| 11 days | Mean (SD) | 228.78 (104.97) | 325.14 (110.16) |
| 11 days | Median [IQR] | 210 [155 - 266] | 360 [258.5 - 401.5] |
| 11 days | Missing / Non-Missing | 4 / 9 | 5 / 7 |
| 12 days | Mean (SD) | 276.67 (130.97) | 319.29 (85.44) |
| 12 days | Median [IQR] | 241 [181.5 - 371] | 310 [269 - 351] |
| 12 days | Missing / Non-Missing | 3 / 6 | 4 / 7 |
| 13 days | Mean (SD) | 255.5 (76.82) | 271.86 (93.71) |
| 13 days | Median [IQR] | 241.5 [195 - 302] | 255 [229.5 - 304.5] |
| 13 days | Missing / Non-Missing | 4 / 4 | 4 / 7 |
| 14 days | Mean (SD) | 230.33 (127.5) | 270.5 (97.04) |
| 14 days | Median [IQR] | 176 [157.5 - 276] | 262.5 [194 - 334] |
| 14 days | Missing / Non-Missing | 1 / 3 | 1 / 8 |

LDH (U/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 296.93 (124.29) | 313.29 (114.7) |
| 0 days | Median [IQR] | 271 [215.75 - 330.5] | 305 [238.5 - 365.25] |
| 0 days | Missing / Non-Missing | 1 / 56 | 4 / 38 |
| 1 days | Mean (SD) | 322.49 (138.25) | 307.1 (123.16) |
| 1 days | Median [IQR] | 311 [233 - 347] | 280 [226.5 - 390] |
| 1 days | Missing / Non-Missing | 24 / 33 | 22 / 20 |
| 2 days | Mean (SD) | 325.92 (128.91) | 322.71 (135.64) |
| 2 days | Median [IQR] | 310 [243.5 - 367] | 342 [222.5 - 389.5] |
| 2 days | Missing / Non-Missing | 18 / 35 | 10 / 31 |
| 3 days | Mean (SD) | 336.78 (145.11) | 358.48 (166.78) |
| 3 days | Median [IQR] | 293 [265 - 357] | 338 [226.5 - 448.5] |
| 3 days | Missing / Non-Missing | 17 / 31 | 13 / 23 |
| 4 days | Mean (SD) | 339.19 (126.81) | 390.95 (206.16) |
| 4 days | Median [IQR] | 298 [262.25 - 363.25] | 332 [247 - 476.25] |
| 4 days | Missing / Non-Missing | 14 / 26 | 15 / 18 |
| 5 days | Mean (SD) | 357 (155.83) | 366.73 (144.83) |
| 5 days | Median [IQR] | 292 [263 - 390] | 297 [275 - 441] |
| 5 days | Missing / Non-Missing | 17 / 21 | 14 / 15 |
| 6 days | Mean (SD) | 320 (115.48) | 341.58 (146.7) |
| 6 days | Median [IQR] | 278.5 [262.5 - 333.5] | 292.5 [240.5 - 418] |
| 6 days | Missing / Non-Missing | 9 / 28 | 14 / 12 |
| 7 days | Mean (SD) | 308.79 (114.26) | 294.47 (92.64) |
| 7 days | Median [IQR] | 263 [226.5 - 370.5] | 287 [216 - 348.5] |
| 7 days | Missing / Non-Missing | 11 / 19 | 3 / 19 |
| 8 days | Mean (SD) | 286.11 (82.28) | 331.25 (94.83) |
| 8 days | Median [IQR] | 256.5 [234.75 - 308.5] | 348.5 [270.75 - 387.5] |
| 8 days | Missing / Non-Missing | 9 / 18 | 9 / 8 |
| 9 days | Mean (SD) | 296.64 (91.3) | 316.17 (88.97) |
| 9 days | Median [IQR] | 296.5 [227.5 - 346.75] | 335.5 [265 - 377.5] |
| 9 days | Missing / Non-Missing | 10 / 14 | 9 / 6 |
| 10 days | Mean (SD) | 261.3 (108.27) | 303.3 (89.6) |
| 10 days | Median [IQR] | 218 [207 - 290] | 324.5 [229 - 362] |
| 10 days | Missing / Non-Missing | 10 / 10 | 4 / 10 |
| 11 days | Mean (SD) | 240 (95.06) | 292.33 (79.45) |
| 11 days | Median [IQR] | 246 [172 - 266.75] | 289 [261.75 - 307.25] |
| 11 days | Missing / Non-Missing | 9 / 8 | 8 / 6 |
| 12 days | Mean (SD) | 266.27 (105.54) | 268.57 (84.02) |
| 12 days | Median [IQR] | 219 [193 - 334] | 291 [217.5 - 326] |
| 12 days | Missing / Non-Missing | 5 / 11 | 6 / 7 |
| 13 days | Mean (SD) | 258.5 (113.96) | 248.4 (100.82) |
| 13 days | Median [IQR] | 224 [184 - 302] | 231 [175 - 317] |
| 13 days | Missing / Non-Missing | 7 / 8 | 6 / 5 |
| 14 days | Mean (SD) | 247.25 (128.28) | 231.8 (84.57) |
| 14 days | Median [IQR] | 201 [145 - 314.5] | 254 [158 - 259] |
| 14 days | Missing / Non-Missing | 2 / 8 | 3 / 5 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 1.14 (0.56) | 1.27 (0.94) |
| 0 days | Median [IQR] | 1 [0.75 - 1.55] | 1.1 [0.9 - 1.4] |
| 0 days | Missing / Non-Missing | 3 / 51 | 1 / 51 |
| 1 days | Mean (SD) | 1.1 (0.47) | 1.2 (0.49) |
| 1 days | Median [IQR] | 1.2 [0.7 - 1.5] | 1.2 [0.83 - 1.4] |
| 1 days | Missing / Non-Missing | 20 / 33 | 18 / 34 |
| 2 days | Mean (SD) | 1.21 (0.62) | 1.28 (0.51) |
| 2 days | Median [IQR] | 1.1 [0.68 - 1.6] | 1.2 [0.95 - 1.6] |
| 2 days | Missing / Non-Missing | 18 / 32 | 10 / 43 |
| 3 days | Mean (SD) | 1.24 (0.6) | 1.36 (0.68) |
| 3 days | Median [IQR] | 1.25 [0.88 - 1.63] | 1.1 [0.9 - 1.8] |
| 3 days | Missing / Non-Missing | 12 / 32 | 12 / 35 |
| 4 days | Mean (SD) | 1.11 (0.61) | 1.3 (0.64) |
| 4 days | Median [IQR] | 1.1 [0.6 - 1.6] | 1.2 [0.8 - 1.65] |
| 4 days | Missing / Non-Missing | 9 / 25 | 14 / 27 |
| 5 days | Mean (SD) | 1.3 (0.63) | 1.37 (0.74) |
| 5 days | Median [IQR] | 1.3 [0.9 - 1.8] | 1.15 [0.78 - 1.83] |
| 5 days | Missing / Non-Missing | 5 / 25 | 12 / 24 |
| 6 days | Mean (SD) | 1.23 (0.75) | 1.4 (0.66) |
| 6 days | Median [IQR] | 1.1 [0.53 - 1.5] | 1.25 [0.88 - 1.8] |
| 6 days | Missing / Non-Missing | 5 / 22 | 12 / 18 |
| 7 days | Mean (SD) | 1.31 (0.78) | 1.37 (0.62) |
| 7 days | Median [IQR] | 1.3 [0.65 - 1.63] | 1.25 [1.05 - 1.83] |
| 7 days | Missing / Non-Missing | 6 / 16 | 7 / 20 |
| 8 days | Mean (SD) | 1.97 (1.93) | 1.34 (0.52) |
| 8 days | Median [IQR] | 1.4 [1 - 2] | 1.4 [0.9 - 1.58] |
| 8 days | Missing / Non-Missing | 3 / 17 | 12 / 12 |
| 9 days | Mean (SD) | 1.46 (0.86) | 1.39 (0.53) |
| 9 days | Median [IQR] | 1.3 [0.85 - 1.65] | 1.1 [1.1 - 1.8] |
| 9 days | Missing / Non-Missing | 4 / 16 | 6 / 13 |
| 10 days | Mean (SD) | 1.69 (0.82) | 1.59 (0.64) |
| 10 days | Median [IQR] | 1.65 [1.25 - 2.15] | 1.5 [1.08 - 2] |
| 10 days | Missing / Non-Missing | 5 / 12 | 5 / 8 |
| 11 days | Mean (SD) | 1.48 (0.75) | 1.43 (0.53) |
| 11 days | Median [IQR] | 1.6 [0.7 - 2] | 1.55 [1.03 - 1.9] |
| 11 days | Missing / Non-Missing | 4 / 9 | 4 / 8 |
| 12 days | Mean (SD) | 1.67 (1.21) | 1.97 (1.08) |
| 12 days | Median [IQR] | 1.3 [0.68 - 2.45] | 2.05 [1.33 - 2.7] |
| 12 days | Missing / Non-Missing | 3 / 6 | 5 / 6 |
| 13 days | Mean (SD) | 1.48 (1.17) | 1.97 (0.89) |
| 13 days | Median [IQR] | 1.05 [0.9 - 1.63] | 2.05 [1.63 - 2.55] |
| 13 days | Missing / Non-Missing | 4 / 4 | 5 / 6 |
| 14 days | Mean (SD) | 1.58 (0.87) | 1.69 (0.81) |
| 14 days | Median [IQR] | 1.65 [0.98 - 2.25] | 1.8 [1.13 - 2.3] |
| 14 days | Missing / Non-Missing | 0 / 4 | 1 / 8 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 1.09 (0.49) | 1.14 (0.56) |
| 0 days | Median [IQR] | 1.1 [0.8 - 1.3] | 1 [0.7 - 1.4] |
| 0 days | Missing / Non-Missing | 2 / 55 | 3 / 39 |
| 1 days | Mean (SD) | 1.04 (0.45) | 1.27 (0.6) |
| 1 days | Median [IQR] | 1 [0.75 - 1.35] | 1.1 [0.75 - 1.6] |
| 1 days | Missing / Non-Missing | 22 / 35 | 15 / 27 |
| 2 days | Mean (SD) | 1.27 (0.6) | 1.38 (0.63) |
| 2 days | Median [IQR] | 1.2 [0.9 - 1.7] | 1.1 [0.9 - 1.8] |
| 2 days | Missing / Non-Missing | 14 / 39 | 6 / 35 |
| 3 days | Mean (SD) | 1.28 (0.5) | 1.16 (0.58) |
| 3 days | Median [IQR] | 1.3 [1 - 1.55] | 1 [0.85 - 1.3] |
| 3 days | Missing / Non-Missing | 17 / 31 | 9 / 27 |
| 4 days | Mean (SD) | 1.15 (0.58) | 1.51 (0.86) |
| 4 days | Median [IQR] | 1.05 [0.63 - 1.58] | 1.3 [0.9 - 1.7] |
| 4 days | Missing / Non-Missing | 10 / 30 | 12 / 21 |
| 5 days | Mean (SD) | 1.17 (0.52) | 1.48 (0.84) |
| 5 days | Median [IQR] | 1.1 [0.75 - 1.55] | 1.35 [1.15 - 1.5] |
| 5 days | Missing / Non-Missing | 15 / 23 | 13 / 16 |
| 6 days | Mean (SD) | 1.19 (0.56) | 1.74 (0.9) |
| 6 days | Median [IQR] | 1.2 [0.7 - 1.4] | 1.65 [1.18 - 2.03] |
| 6 days | Missing / Non-Missing | 10 / 27 | 10 / 16 |
| 7 days | Mean (SD) | 1.29 (0.67) | 1.51 (0.43) |
| 7 days | Median [IQR] | 1.25 [0.85 - 1.58] | 1.3 [1.2 - 1.9] |
| 7 days | Missing / Non-Missing | 10 / 20 | 3 / 19 |
| 8 days | Mean (SD) | 1.83 (1.66) | 1.81 (0.68) |
| 8 days | Median [IQR] | 1.55 [1.08 - 1.88] | 1.8 [1.3 - 2.3] |
| 8 days | Missing / Non-Missing | 3 / 24 | 7 / 10 |
| 9 days | Mean (SD) | 1.41 (0.83) | 1.76 (0.65) |
| 9 days | Median [IQR] | 1.1 [0.7 - 1.9] | 1.8 [1.3 - 2.3] |
| 9 days | Missing / Non-Missing | 7 / 17 | 8 / 7 |
| 10 days | Mean (SD) | 1.75 (0.85) | 1.7 (0.72) |
| 10 days | Median [IQR] | 1.9 [1.1 - 2.25] | 1.75 [1.18 - 1.9] |
| 10 days | Missing / Non-Missing | 8 / 12 | 4 / 10 |
| 11 days | Mean (SD) | 1.45 (1.07) | 1.73 (0.59) |
| 11 days | Median [IQR] | 1.3 [0.55 - 2.1] | 1.65 [1.48 - 1.88] |
| 11 days | Missing / Non-Missing | 9 / 8 | 6 / 8 |
| 12 days | Mean (SD) | 1.73 (0.99) | 1.92 (1.07) |
| 12 days | Median [IQR] | 1.65 [0.83 - 2.53] | 1.4 [1.25 - 2.55] |
| 12 days | Missing / Non-Missing | 4 / 12 | 6 / 7 |
| 13 days | Mean (SD) | 1.59 (0.94) | 2 (0.63) |
| 13 days | Median [IQR] | 1.1 [1 - 2.4] | 1.9 [1.65 - 2.05] |
| 13 days | Missing / Non-Missing | 6 / 9 | 4 / 7 |
| 14 days | Mean (SD) | 1.5 (0.83) | 2.03 (1.04) |
| 14 days | Median [IQR] | 1.6 [0.83 - 2.23] | 1.65 [1.43 - 2.7] |
| 14 days | Missing / Non-Missing | 2 / 8 | 2 / 6 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 4.64 (2.26) | 4.84 (2.52) |
| 0 days | Median [IQR] | 3.9 [3.1 - 5.3] | 4.7 [2.65 - 7] |
| 0 days | Missing / Non-Missing | 3 / 51 | 1 / 51 |
| 1 days | Mean (SD) | 4.75 (2.72) | 4.74 (3.13) |
| 1 days | Median [IQR] | 3.9 [3.1 - 5.7] | 4 [2.38 - 5.88] |
| 1 days | Missing / Non-Missing | 20 / 33 | 18 / 34 |
| 2 days | Mean (SD) | 5.31 (3.13) | 4.81 (3.3) |
| 2 days | Median [IQR] | 4.6 [3.2 - 6.1] | 3.7 [2.7 - 6.4] |
| 2 days | Missing / Non-Missing | 17 / 33 | 10 / 43 |
| 3 days | Mean (SD) | 4.68 (3.39) | 5.94 (3.4) |
| 3 days | Median [IQR] | 3.85 [2.98 - 5.23] | 4.7 [3.4 - 8.25] |
| 3 days | Missing / Non-Missing | 12 / 32 | 12 / 35 |
| 4 days | Mean (SD) | 5.6 (4.96) | 5.75 (3.78) |
| 4 days | Median [IQR] | 4.5 [3.25 - 5.35] | 4.4 [3.1 - 8.1] |
| 4 days | Missing / Non-Missing | 8 / 26 | 14 / 27 |
| 5 days | Mean (SD) | 5.34 (4.04) | 5.74 (3.58) |
| 5 days | Median [IQR] | 4.4 [3.48 - 6.1] | 4.6 [3.68 - 5.43] |
| 5 days | Missing / Non-Missing | 6 / 24 | 12 / 24 |
| 6 days | Mean (SD) | 5.27 (3.8) | 6.68 (4.46) |
| 6 days | Median [IQR] | 4.55 [3.6 - 6.05] | 4.35 [3.85 - 8.43] |
| 6 days | Missing / Non-Missing | 5 / 22 | 12 / 18 |
| 7 days | Mean (SD) | 5.36 (4) | 6.61 (3.94) |
| 7 days | Median [IQR] | 3.95 [2.88 - 6.38] | 4.85 [3.8 - 8.5] |
| 7 days | Missing / Non-Missing | 6 / 16 | 7 / 20 |
| 8 days | Mean (SD) | 6.05 (4.06) | 7.37 (3.76) |
| 8 days | Median [IQR] | 5.2 [3.8 - 7.2] | 6.5 [4.08 - 9.65] |
| 8 days | Missing / Non-Missing | 3 / 17 | 12 / 12 |
| 9 days | Mean (SD) | 6.28 (3.4) | 6.33 (3.8) |
| 9 days | Median [IQR] | 5.85 [4.68 - 7.15] | 5.4 [3.9 - 7.7] |
| 9 days | Missing / Non-Missing | 4 / 16 | 6 / 13 |
| 10 days | Mean (SD) | 6.28 (3.59) | 7.51 (4.16) |
| 10 days | Median [IQR] | 5.7 [3.88 - 7.48] | 6.3 [5.18 - 8.45] |
| 10 days | Missing / Non-Missing | 5 / 12 | 5 / 8 |
| 11 days | Mean (SD) | 6.35 (2.99) | 6.13 (3.17) |
| 11 days | Median [IQR] | 6.7 [4.2 - 8.2] | 5.05 [4.33 - 7.4] |
| 11 days | Missing / Non-Missing | 4 / 9 | 4 / 8 |
| 12 days | Mean (SD) | 7.6 (2.63) | 9.83 (4.48) |
| 12 days | Median [IQR] | 7.25 [5.75 - 9.65] | 8.65 [6.15 - 12.5] |
| 12 days | Missing / Non-Missing | 3 / 6 | 5 / 6 |
| 13 days | Mean (SD) | 8.48 (3.02) | 7.77 (3.78) |
| 13 days | Median [IQR] | 8.85 [6.43 - 10.9] | 6.95 [4.95 - 10.83] |
| 13 days | Missing / Non-Missing | 4 / 4 | 5 / 6 |
| 14 days | Mean (SD) | 8.7 (4.86) | 6.28 (2.51) |
| 14 days | Median [IQR] | 6.9 [5.95 - 10.55] | 6.45 [4.43 - 8.1] |
| 14 days | Missing / Non-Missing | 1 / 3 | 1 / 8 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 5.24 (3.33) | 5.23 (3.24) |
| 0 days | Median [IQR] | 4.45 [3.2 - 6.25] | 4.3 [2.55 - 7.6] |
| 0 days | Missing / Non-Missing | 3 / 54 | 3 / 39 |
| 1 days | Mean (SD) | 6.05 (4.51) | 4.57 (2.78) |
| 1 days | Median [IQR] | 4.6 [3.4 - 7.1] | 3.8 [2.35 - 6.15] |
| 1 days | Missing / Non-Missing | 22 / 35 | 15 / 27 |
| 2 days | Mean (SD) | 5.83 (3.41) | 4.7 (2.91) |
| 2 days | Median [IQR] | 4.9 [3.35 - 7.4] | 4.1 [2.45 - 6.2] |
| 2 days | Missing / Non-Missing | 13 / 40 | 6 / 35 |
| 3 days | Mean (SD) | 4.91 (3.37) | 4.75 (3.09) |
| 3 days | Median [IQR] | 4.6 [3 - 6.3] | 4.5 [2.5 - 6.35] |
| 3 days | Missing / Non-Missing | 17 / 31 | 9 / 27 |
| 4 days | Mean (SD) | 6 (4.44) | 5.13 (2.85) |
| 4 days | Median [IQR] | 5.05 [3.73 - 6.38] | 4.8 [3.1 - 7.2] |
| 4 days | Missing / Non-Missing | 10 / 30 | 12 / 21 |
| 5 days | Mean (SD) | 6.39 (4.06) | 5.45 (2.14) |
| 5 days | Median [IQR] | 5.1 [4.2 - 7.4] | 5.55 [3.83 - 6.45] |
| 5 days | Missing / Non-Missing | 15 / 23 | 13 / 16 |
| 6 days | Mean (SD) | 6 (3.47) | 5.64 (2.44) |
| 6 days | Median [IQR] | 5.3 [4.2 - 6.8] | 5.2 [4.1 - 6.8] |
| 6 days | Missing / Non-Missing | 10 / 27 | 10 / 16 |
| 7 days | Mean (SD) | 6.27 (3.35) | 5.98 (2.06) |
| 7 days | Median [IQR] | 5.4 [4.15 - 7.88] | 5.6 [4.65 - 7.55] |
| 7 days | Missing / Non-Missing | 10 / 20 | 3 / 19 |
| 8 days | Mean (SD) | 6.96 (3.71) | 5.94 (1.83) |
| 8 days | Median [IQR] | 5.75 [4.7 - 8.43] | 6.2 [4.83 - 7.33] |
| 8 days | Missing / Non-Missing | 3 / 24 | 7 / 10 |
| 9 days | Mean (SD) | 6.84 (3.04) | 8.23 (3.48) |
| 9 days | Median [IQR] | 6 [5 - 7.8] | 7.7 [5.9 - 9.45] |
| 9 days | Missing / Non-Missing | 7 / 17 | 8 / 7 |
| 10 days | Mean (SD) | 6.83 (3.38) | 7.54 (3.64) |
| 10 days | Median [IQR] | 6.05 [4.65 - 8.5] | 5.9 [5.13 - 8.98] |
| 10 days | Missing / Non-Missing | 8 / 12 | 4 / 10 |
| 11 days | Mean (SD) | 7.46 (1.77) | 8.23 (3.54) |
| 11 days | Median [IQR] | 6.9 [6.2 - 9.1] | 8.4 [5.68 - 9.75] |
| 11 days | Missing / Non-Missing | 8 / 9 | 6 / 8 |
| 12 days | Mean (SD) | 7.13 (2.97) | 8.1 (3.43) |
| 12 days | Median [IQR] | 6.25 [5 - 10] | 7.5 [6.65 - 10.78] |
| 12 days | Missing / Non-Missing | 4 / 12 | 5 / 8 |
| 13 days | Mean (SD) | 9.05 (4.83) | 8.53 (3.09) |
| 13 days | Median [IQR] | 7.1 [6 - 11.2] | 9.1 [5.98 - 10.88] |
| 13 days | Missing / Non-Missing | 6 / 9 | 5 / 6 |
| 14 days | Mean (SD) | 8.48 (3.72) | 7.42 (3.62) |
| 14 days | Median [IQR] | 7 [6.18 - 10.08] | 6.75 [4.83 - 10.25] |
| 14 days | Missing / Non-Missing | 2 / 8 | 2 / 6 |













Procalcitonin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 0.42 (1.24) | 0.53 (1.79) |
| 0 days | Median [IQR] | 0.1 [0.1 - 0.19] | 0.13 [0.1 - 0.29] |
| 0 days | Missing / Non-Missing | 19 / 35 | 15 / 37 |
| 1 days | Mean (SD) | 0.99 (2.41) | 0.33 (0.34) |
| 1 days | Median [IQR] | 0.14 [0.1 - 0.4] | 0.16 [0.1 - 0.47] |
| 1 days | Missing / Non-Missing | 32 / 21 | 38 / 14 |
| 2 days | Mean (SD) | 0.95 (2.27) | 0.46 (0.92) |
| 2 days | Median [IQR] | 0.15 [0.1 - 0.3] | 0.2 [0.1 - 0.45] |
| 2 days | Missing / Non-Missing | 29 / 21 | 26 / 27 |
| 3 days | Mean (SD) | 0.2 (0.23) | 0.25 (0.26) |
| 3 days | Median [IQR] | 0.1 [0.1 - 0.18] | 0.19 [0.1 - 0.28] |
| 3 days | Missing / Non-Missing | 22 / 22 | 26 / 21 |
| 4 days | Mean (SD) | 0.41 (0.82) | 0.4 (0.38) |
| 4 days | Median [IQR] | 0.12 [0.1 - 0.22] | 0.23 [0.14 - 0.51] |
| 4 days | Missing / Non-Missing | 19 / 15 | 29 / 12 |
| 5 days | Mean (SD) | 0.25 (0.39) | 0.4 (0.52) |
| 5 days | Median [IQR] | 0.11 [0.1 - 0.22] | 0.17 [0.1 - 0.48] |
| 5 days | Missing / Non-Missing | 13 / 17 | 25 / 11 |
| 6 days | Mean (SD) | 0.42 (1) | 0.24 (0.34) |
| 6 days | Median [IQR] | 0.12 [0.1 - 0.23] | 0.1 [0.1 - 0.18] |
| 6 days | Missing / Non-Missing | 13 / 14 | 19 / 11 |
| 7 days | Mean (SD) | 0.15 (0.09) | 0.28 (0.22) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.19] | 0.2 [0.1 - 0.41] |
| 7 days | Missing / Non-Missing | 11 / 11 | 16 / 11 |
| 8 days | Mean (SD) | 0.16 (0.1) | 0.36 (0.38) |
| 8 days | Median [IQR] | 0.11 [0.1 - 0.19] | 0.12 [0.1 - 0.55] |
| 8 days | Missing / Non-Missing | 9 / 11 | 16 / 8 |
| 9 days | Mean (SD) | 0.27 (0.46) | 0.31 (0.37) |
| 9 days | Median [IQR] | 0.11 [0.1 - 0.19] | 0.1 [0.1 - 0.41] |
| 9 days | Missing / Non-Missing | 8 / 12 | 10 / 9 |
| 10 days | Mean (SD) | 0.15 (0.1) | 0.26 (0.23) |
| 10 days | Median [IQR] | 0.1 [0.1 - 0.16] | 0.1 [0.1 - 0.4] |
| 10 days | Missing / Non-Missing | 10 / 7 | 8 / 5 |
| 11 days | Mean (SD) | 0.1 (0.01) | 0.54 (0.45) |
| 11 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.42 [0.32 - 0.58] |
| 11 days | Missing / Non-Missing | 8 / 5 | 6 / 6 |
| 12 days | Mean (SD) | 0.35 (0.61) | 0.45 (0.57) |
| 12 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.21 [0.1 - 0.56] |
| 12 days | Missing / Non-Missing | 3 / 6 | 7 / 4 |
| 13 days | Mean (SD) | 0.11 (0.04) | 0.45 (0.5) |
| 13 days | Median [IQR] | 0.1 [0.09 - 0.13] | 0.2 [0.1 - 0.68] |
| 13 days | Missing / Non-Missing | 5 / 3 | 5 / 6 |
| 14 days | Mean (SD) | 0.17 (0.15) | 0.24 (0.17) |
| 14 days | Median [IQR] | 0.17 [0.11 - 0.22] | 0.17 [0.11 - 0.35] |
| 14 days | Missing / Non-Missing | 2 / 2 | 3 / 6 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 0.45 (1.23) | 0.22 (0.19) |
| 0 days | Median [IQR] | 0.11 [0.1 - 0.17] | 0.16 [0.1 - 0.2] |
| 0 days | Missing / Non-Missing | 20 / 37 | 13 / 29 |
| 1 days | Mean (SD) | 1.03 (2.6) | 1.92 (5.38) |
| 1 days | Median [IQR] | 0.14 [0.1 - 0.27] | 0.18 [0.1 - 0.27] |
| 1 days | Missing / Non-Missing | 39 / 18 | 27 / 15 |
| 2 days | Mean (SD) | 0.83 (2.06) | 1.48 (5.62) |
| 2 days | Median [IQR] | 0.17 [0.1 - 0.29] | 0.18 [0.1 - 0.38] |
| 2 days | Missing / Non-Missing | 27 / 26 | 15 / 26 |
| 3 days | Mean (SD) | 0.24 (0.36) | 1.22 (4.15) |
| 3 days | Median [IQR] | 0.12 [0.1 - 0.2] | 0.12 [0.1 - 0.29] |
| 3 days | Missing / Non-Missing | 25 / 23 | 18 / 18 |
| 4 days | Mean (SD) | 1.42 (3.89) | 0.93 (2.2) |
| 4 days | Median [IQR] | 0.12 [0.1 - 0.23] | 0.19 [0.1 - 0.54] |
| 4 days | Missing / Non-Missing | 26 / 14 | 18 / 15 |
| 5 days | Mean (SD) | 1.26 (3.58) | 0.79 (1.36) |
| 5 days | Median [IQR] | 0.11 [0.1 - 0.38] | 0.23 [0.2 - 0.7] |
| 5 days | Missing / Non-Missing | 24 / 14 | 20 / 9 |
| 6 days | Mean (SD) | 0.8 (2.19) | 0.59 (0.79) |
| 6 days | Median [IQR] | 0.13 [0.1 - 0.21] | 0.2 [0.11 - 0.7] |
| 6 days | Missing / Non-Missing | 17 / 20 | 17 / 9 |
| 7 days | Mean (SD) | 0.13 (0.09) | 0.34 (0.49) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.13] | 0.11 [0.1 - 0.35] |
| 7 days | Missing / Non-Missing | 17 / 13 | 7 / 15 |
| 8 days | Mean (SD) | 0.37 (0.85) | 0.33 (0.23) |
| 8 days | Median [IQR] | 0.1 [0.1 - 0.2] | 0.4 [0.1 - 0.51] |
| 8 days | Missing / Non-Missing | 13 / 14 | 10 / 7 |
| 9 days | Mean (SD) | 0.51 (0.78) | 0.4 (0.27) |
| 9 days | Median [IQR] | 0.14 [0.1 - 0.3] | 0.43 [0.17 - 0.5] |
| 9 days | Missing / Non-Missing | 14 / 10 | 9 / 6 |
| 10 days | Mean (SD) | 0.31 (0.53) | 0.25 (0.18) |
| 10 days | Median [IQR] | 0.11 [0.09 - 0.22] | 0.19 [0.12 - 0.36] |
| 10 days | Missing / Non-Missing | 12 / 8 | 8 / 6 |
| 11 days | Mean (SD) | 0.1 (0.06) | 1.2 (2.41) |
| 11 days | Median [IQR] | 0.1 [0.09 - 0.11] | 0.23 [0.11 - 0.45] |
| 11 days | Missing / Non-Missing | 11 / 6 | 8 / 6 |
| 12 days | Mean (SD) | 0.28 (0.47) | 0.17 (0.09) |
| 12 days | Median [IQR] | 0.1 [0.1 - 0.15] | 0.13 [0.12 - 0.2] |
| 12 days | Missing / Non-Missing | 5 / 11 | 10 / 3 |
| 13 days | Mean (SD) | 0.48 (0.85) | 0.18 (0.13) |
| 13 days | Median [IQR] | 0.16 [0.1 - 0.25] | 0.13 [0.1 - 0.17] |
| 13 days | Missing / Non-Missing | 8 / 7 | 6 / 5 |
| 14 days | Mean (SD) | 0.76 (1.1) | 0.26 (0.29) |
| 14 days | Median [IQR] | 0.29 [0.22 - 0.83] | 0.13 [0.11 - 0.28] |
| 14 days | Missing / Non-Missing | 6 / 4 | 4 / 4 |

### Plots



### Efficacy estimates

CRP (mg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -12.137 | -17.163 | -7.110 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -9.267 | -13.581 | -4.953 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 2.870 | -3.248 | 8.988 | 0.358 |
| Day 10 level by treatment | Standard of care (SOC) | 38.049 | 24.883 | 51.216 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 45.755 | 29.943 | 61.568 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 7.706 | -11.335 | 26.748 | 0.428 |

CRP (mg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -10.175 | -14.413 | -5.938 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -15.972 | -22.263 | -9.681 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | -5.797 | -12.788 | 1.194 | 0.104 |
| Day 10 level by treatment | Standard of care (SOC) | 57.619 | 39.927 | 75.311 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 31.300 | 20.194 | 42.406 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -26.320 | -45.873 | -6.766 | 0.008 |

Ferritin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 17.554 | 0.123 | 34.986 | 0.048 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -5.469 | -25.492 | 14.554 | 0.592 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -23.023 | -49.598 | 3.552 | 0.090 |
| Day 10 level by treatment | Standard of care (SOC) | 698.297 | 506.292 | 890.301 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 997.752 | 722.018 | 1273.487 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 299.456 | -12.489 | 611.401 | 0.060 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -10.661 | -26.617 | 5.295 | 0.190 |
| Slope 1st week by treatment | Remdesivir + SOC | -21.849 | -46.510 | 2.812 | 0.082 |
| Difference in 1st week slope | Remdesivir + SOC | -11.188 | -40.370 | 17.994 | 0.452 |
| Day 10 level by treatment | Standard of care (SOC) | 779.953 | 578.299 | 981.607 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 798.289 | 559.139 | 1037.438 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | 18.336 | -272.241 | 308.913 | 0.902 |

LDH (U/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -3.473 | -6.964 | 0.018 | 0.051 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -5.140 | -8.829 | -1.452 | 0.006 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -1.668 | -6.728 | 3.393 | 0.518 |
| Day 10 level by treatment | Standard of care (SOC) | 230.155 | 203.904 | 256.406 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 258.969 | 229.847 | 288.091 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 28.814 | -10.146 | 67.774 | 0.147 |

LDH (U/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -4.028 | -7.059 | -0.997 | 0.009 |
| Slope 1st week by treatment | Remdesivir + SOC | -6.754 | -10.543 | -2.964 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | -2.725 | -7.553 | 2.102 | 0.269 |
| Day 10 level by treatment | Standard of care (SOC) | 243.136 | 219.164 | 267.108 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 234.831 | 207.135 | 262.527 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -8.304 | -44.766 | 28.157 | 0.655 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.096 | 0.066 | 0.127 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.047 | 0.020 | 0.075 | 0.001 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -0.049 | -0.090 | -0.008 | 0.018 |
| Day 10 level by treatment | Standard of care (SOC) | 1.858 | 1.577 | 2.138 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 1.785 | 1.522 | 2.048 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | -0.073 | -0.447 | 0.301 | 0.702 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.075 | 0.052 | 0.099 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.095 | 0.063 | 0.127 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | 0.020 | -0.020 | 0.060 | 0.325 |
| Day 10 level by treatment | Standard of care (SOC) | 1.719 | 1.500 | 1.937 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 1.978 | 1.687 | 2.268 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | 0.259 | -0.097 | 0.615 | 0.154 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.009 | -0.091 | 0.073 | 0.829 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.130 | 0.034 | 0.226 | 0.008 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.139 | 0.012 | 0.265 | 0.032 |
| Day 10 level by treatment | Standard of care (SOC) | 4.788 | 4.066 | 5.509 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 6.642 | 5.639 | 7.646 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 1.855 | 0.636 | 3.073 | 0.003 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.021 | -0.072 | 0.114 | 0.661 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.007 | -0.092 | 0.106 | 0.891 |
| Difference in 1st week slope | Remdesivir + SOC | -0.014 | -0.149 | 0.121 | 0.841 |
| Day 10 level by treatment | Standard of care (SOC) | 5.748 | 4.879 | 6.618 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 5.463 | 4.490 | 6.436 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -0.285 | -1.571 | 1.001 | 0.664 |

Procalcitonin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.022 | -0.034 | -0.011 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -0.022 | -0.036 | -0.008 | 0.002 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.000 | -0.017 | 0.018 | 0.983 |
| Day 10 level by treatment | Standard of care (SOC) | 0.141 | 0.093 | 0.188 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 0.216 | 0.144 | 0.287 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 0.075 | -0.007 | 0.157 | 0.073 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.024 | -0.042 | -0.006 | 0.007 |
| Slope 1st week by treatment | Remdesivir + SOC | -0.053 | -0.085 | -0.022 | 0.001 |
| Difference in 1st week slope | Remdesivir + SOC | -0.029 | -0.064 | 0.005 | 0.097 |
| Day 10 level by treatment | Standard of care (SOC) | 0.251 | 0.155 | 0.347 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 0.195 | 0.109 | 0.280 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -0.056 | -0.176 | 0.064 | 0.360 |

## SARS-CoV2 antibodies at day 90

### Descriptives

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Receptor-bindind domain | Mean (SD) | 56.1 (46.9) | 66.5 (43.3) |
|  | Median (IQR) | 54 (11.3 - 90.4) | 57.2 (33.9 - 101.5) |
| Normalised receptor-binding domain | Mean (SD) | 16.6 (10.5) | 18.7 (11.5) |
|  | Median (IQR) | 15.7 (7.6 - 22.5) | 15.3 (11 - 25.6) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.42 (0.63) | 1 (0.68) |
|  | Median (IQR) | 1.44 (1.18 - 1.8) | 0.94 (0.38 - 1.54) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| Receptor-bindind domain | Mean (SD) | 46.4 (37.2) | 60.5 (42.4) |
|  | Median (IQR) | 40.4 (11.3 - 70.3) | 57.4 (23.8 - 95.5) |
| Normalised receptor-binding domain | Mean (SD) | 15.4 (10.4) | 18.1 (11.8) |
|  | Median (IQR) | 15 (7 - 22.5) | 17.7 (9 - 26.4) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.24 (0.7) | 1.2 (0.56) |
|  | Median (IQR) | 1.22 (0.78 - 1.73) | 1.24 (0.84 - 1.53) |

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 56.1 (42.7 to 69.6) | 66.5 (51.9 to 81.1) | 10.4 (-9.4 to 30.3) |
| Normalised receptor-binding domain | 16.6 (13.3 to 19.8) | 18.7 (15.2 to 22.3) | 2.2 (-2.6 to 7) |
| log10 ACE2 receptor-binding domain | 1.42 (1.22 to 1.61) | 1 (0.79 to 1.21) | -0.42 (-0.71 to -0.13) |

Estimates are presented with 95% confidence limits



Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 46.4 (35.7 to 57.2) | 60.5 (47.1 to 73.9) | 14 (-3.1 to 31.2) |
| Normalised receptor-binding domain | 15.4 (12.4 to 18.4) | 18.1 (14.3 to 21.8) | 2.7 (-2.1 to 7.5) |
| log10 ACE2 receptor-binding domain | 1.24 (1.06 to 1.41) | 1.2 (0.98 to 1.42) | -0.03 (-0.32 to 0.25) |



Estimates are presented with 95% confidence limits

## Time to last discharge

### HCQ



### Remdesivir



# Adverse Events

## AE Summary

Summary of Adverse Events

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Number of AEs | [31] 22 (25.3%) | [26] 17 (32.7%) | [36] 19 (45.2%) |
| Number of patients with any AEs? | 22 (25.3%) | 17 (32.7%) | 19 (45.2%) |
| Number of patients with one AE | 18 (20.7%) | 12 (23.1%) | 10 (23.8%) |
| Number of patients with two AE | 1 (1.1%) | 1 (1.9%) | 4 (9.5%) |
| Number of patients with three or more AEs | 3 (3.4%) | 4 (7.7%) | 5 (11.9%) |
| Number of SAEs | [15] 11 (12.6%) | [11] 9 (17.3%) | [19] 11 (26.2%) |
| Number of patients with any SAEs? | 11 (12.6%) | 9 (17.3%) | 11 (26.2%) |

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

## By System Organ Class and Preferred Term

Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Blood and lymphatic system disorders | #Total |  |  | [2] 1 (2.4%) |
|  | Leukopenia |  |  | [1] 1 (2.4%) |
|  | Thrombocytopenia |  |  | [1] 1 (2.4%) |
| Cardiac disorders | #Total | [1] 1 (1.1%) | [2] 1 (1.9%) | [1] 1 (2.4%) |
|  | Arrhythmia |  | [2] 1 (1.9%) |  |
|  | Ventricular tachycardia | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Gastrointestinal disorders | #Total | [5] 5 (5.7%) | [4] 3 (5.8%) | [1] 1 (2.4%) |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea |  | [1] 1 (1.9%) |  |
|  | Diarrhoea haemorrhagic |  | [1] 1 (1.9%) |  |
|  | Gastrooesophageal reflux disease | [1] 1 (1.1%) |  |  |
|  | Intestinal pseudo-obstruction |  |  | [1] 1 (2.4%) |
|  | Nausea | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Pancreatic failure | [1] 1 (1.1%) |  |  |
|  | Vomiting | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| General disorders and administration site conditions | #Total | [2] 2 (2.3%) | [1] 1 (1.9%) | [2] 2 (4.8%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration | [1] 1 (1.1%) |  |  |
|  | Medical device site reaction |  |  | [1] 1 (2.4%) |
|  | Pyrexia | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) | [3] 3 (7.1%) |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Infection |  |  | [1] 1 (2.4%) |
|  | Pneumonia bacterial |  |  | [2] 2 (4.8%) |
|  | Superinfection bacterial |  | [1] 1 (1.9%) |  |
| Injury, poisoning and procedural complications | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax |  | [1] 1 (1.9%) |  |
| Investigations | #Total | [4] 4 (4.6%) | [8] 5 (9.6%) | [7] 4 (9.5%) |
|  | Alanine aminotransferase increased |  | [4] 3 (5.8%) |  |
|  | Amylase increased |  |  | [1] 1 (2.4%) |
|  | Aspartate aminotransferase increased | [1] 1 (1.1%) | [2] 2 (3.8%) | [2] 2 (4.8%) |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Electrocardiogram QT prolonged | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Fibrin D dimer increased |  |  | [1] 1 (2.4%) |
|  | Gamma-glutamyltransferase increased |  |  | [1] 1 (2.4%) |
|  | Hepatic enzyme increased |  | [2] 2 (3.8%) |  |
|  | Myocardial necrosis marker increased | [1] 1 (1.1%) |  |  |
|  | Neutrophil count decreased |  |  | [1] 1 (2.4%) |
| Metabolism and nutrition disorders | #Total |  | [1] 1 (1.9%) |  |
|  | Hypercalcaemia |  | [1] 1 (1.9%) |  |
| Musculoskeletal and connective tissue disorders | #Total | [4] 2 (2.3%) |  |  |
|  | Arthralgia | [1] 1 (1.1%) |  |  |
|  | Arthritis reactive | [1] 1 (1.1%) |  |  |
|  | Joint swelling | [1] 1 (1.1%) |  |  |
|  | Tendonitis | [1] 1 (1.1%) |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total |  |  | [1] 1 (2.4%) |
|  | Neoplasm malignant |  |  | [1] 1 (2.4%) |
| Nervous system disorders | #Total | [1] 1 (1.1%) | [2] 2 (3.8%) | [2] 2 (4.8%) |
|  | Haemorrhage intracranial |  | [1] 1 (1.9%) |  |
|  | Headache |  |  | [1] 1 (2.4%) |
|  | Loss of consciousness |  |  | [1] 1 (2.4%) |
|  | Syncope | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Renal and urinary disorders | #Total | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Renal failure | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Respiratory, thoracic and mediastinal disorders | #Total | [8] 7 (8%) | [5] 5 (9.6%) | [14] 9 (21.4%) |
|  | Bronchopleural fistula |  |  | [1] 1 (2.4%) |
|  | Chronic obstructive pulmonary disease |  |  | [2] 1 (2.4%) |
|  | Cough |  |  | [1] 1 (2.4%) |
|  | Dyspnoea | [1] 1 (1.1%) |  | [3] 1 (2.4%) |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [4] 4 (4.6%) | [1] 1 (1.9%) | [3] 2 (4.8%) |
|  | Respiratory failure | [2] 2 (2.3%) | [4] 4 (7.7%) | [4] 3 (7.1%) |
| Skin and subcutaneous tissue disorders | #Total |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | Alopecia |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
| Vascular disorders | #Total | [2] 2 (2.3%) |  | [1] 1 (2.4%) |
|  | Hypotension |  |  | [1] 1 (2.4%) |
|  | Thrombophlebitis | [1] 1 (1.1%) |  |  |
|  | Thrombosis | [1] 1 (1.1%) |  |  |

## Serious Adverse Events

Serious Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Gastrointestinal disorders | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea haemorrhagic |  | [1] 1 (1.9%) |  |
| General disorders and administration site conditions | #Total | [2] 2 (2.3%) |  | [1] 1 (2.4%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration | [1] 1 (1.1%) |  |  |
|  | Pyrexia | [1] 1 (1.1%) |  |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Pneumonia bacterial |  |  | [1] 1 (2.4%) |
|  | Superinfection bacterial |  | [1] 1 (1.9%) |  |
| Injury, poisoning and procedural complications | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax |  | [1] 1 (1.9%) |  |
| Investigations | #Total | [1] 1 (1.1%) | [3] 3 (5.8%) | [1] 1 (2.4%) |
|  | Alanine aminotransferase increased |  | [1] 1 (1.9%) |  |
|  | Aspartate aminotransferase increased |  |  | [1] 1 (2.4%) |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Hepatic enzyme increased |  | [2] 2 (3.8%) |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total |  |  | [1] 1 (2.4%) |
|  | Neoplasm malignant |  |  | [1] 1 (2.4%) |
| Nervous system disorders | #Total |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | Haemorrhage intracranial |  | [1] 1 (1.9%) |  |
|  | Loss of consciousness |  |  | [1] 1 (2.4%) |
| Renal and urinary disorders | #Total | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Renal failure | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Respiratory, thoracic and mediastinal disorders | #Total | [7] 6 (6.9%) | [4] 4 (7.7%) | [13] 8 (19%) |
|  | Bronchopleural fistula |  |  | [1] 1 (2.4%) |
|  | Chronic obstructive pulmonary disease |  |  | [2] 1 (2.4%) |
|  | Dyspnoea | [1] 1 (1.1%) |  | [3] 1 (2.4%) |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [3] 3 (3.4%) | [1] 1 (1.9%) | [3] 2 (4.8%) |
|  | Respiratory failure | [2] 2 (2.3%) | [3] 3 (5.8%) | [4] 3 (7.1%) |

## Suspected Unexpected Serious Adverse Reaction

Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

|  |  |  |
| --- | --- | --- |
| System Organ Class | Preferred Term | Hydroxychloroquine + SOC |
| Gastrointestinal disorders | #Total | [1] 1 (1.9%) |
|  | Diarrhoea haemorrhagic | [1] 1 (1.9%) |

END